



## Clinical trial results:

**A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects.**

### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2009-010269-21   |
| Trial protocol           | DE ES FR IT      |
| Global end of trial date | 22 December 2016 |

### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1 (current)     |
| This version publication date  | 30 December 2017 |
| First version publication date | 30 December 2017 |

### Trial information

#### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 112276 |
|-----------------------|--------|

#### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

### Sponsors

|                              |                                                            |
|------------------------------|------------------------------------------------------------|
| Sponsor organisation name    | ViiV Healthcare                                            |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, |
| Public contact               | GSK Response Center, GlaxoSmithKline, 1 866-435-7343,      |
| Scientific contact           | GSK Response Center, GlaxoSmithKline, 1 866-435-7343,      |

Notes:

### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |                  |
|------------------------------------------------------|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 19 July 2017     |
| Is this the analysis of the primary completion data? | No               |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 22 December 2016 |
| Was the trial ended prematurely?                     | No               |

Notes:

## General information about the trial

Main objective of the trial:

To select a GSK1349572 once daily dose for further evaluation in Phase III based on a comparison of the Week 16 antiviral activity and tolerability of a range of oral doses of GSK1349572 in Human Immunodeficiency Virus Type 1 (HIV-1) infected therapy-naïve adult participants.

Protection of trial subjects:

99999

Background therapy: -

Evidence for comparator: -

|                                                           |              |
|-----------------------------------------------------------|--------------|
| Actual start date of recruitment                          | 30 July 2009 |
| Long term follow-up planned                               | Yes          |
| Long term follow-up rationale                             | Safety       |
| Long term follow-up duration                              | 86 Months    |
| Independent data monitoring committee (IDMC) involvement? | No           |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                        |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | United States: 81      |
| Country: Number of subjects enrolled | France: 18             |
| Country: Number of subjects enrolled | Germany: 28            |
| Country: Number of subjects enrolled | Italy: 28              |
| Country: Number of subjects enrolled | Russian Federation: 19 |
| Country: Number of subjects enrolled | Spain: 31              |
| Worldwide total number of subjects   | 205                    |
| EEA total number of subjects         | 105                    |

Notes:

### Subjects enrolled per age group

|                                           |   |
|-------------------------------------------|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 0 |

|                           |     |
|---------------------------|-----|
| Children (2-11 years)     | 0   |
| Adolescents (12-17 years) | 0   |
| Adults (18-64 years)      | 203 |
| From 65 to 84 years       | 2   |
| 85 years and over         | 0   |

## Subject disposition

### Recruitment

Recruitment details:

Randomization Phase participants received Dolutegravir (DTG 10, 25 or 50 milligrams[mg]) with Placebo/Efavirenz (EFV) for 96 Weeks . DTG participants who completed 96 Weeks continued or were switched to receive DTG 50 mg in Open label phase until DTG was locally available.

### Pre-assignment

Screening details:

A total of 278 par were screened of which 70 were screen failures and 208 were randomized; 205 received at least one dose of study medication and comprised the Intent-To-Treat exposed (ITT-E) population. 17 participants out of 155 from DTG arm withdrew during Randomization phase and total 138 participants were enrolled in an Open-label phase.

### Period 1

|                              |                             |
|------------------------------|-----------------------------|
| Period 1 title               | Randomization Phase 96 Week |
| Is this the baseline period? | Yes                         |
| Allocation method            | Randomised - controlled     |
| Blinding used                | Double blind                |
| Roles blinded                | Subject, Investigator       |

### Arms

|                              |              |
|------------------------------|--------------|
| Are arms mutually exclusive? | Yes          |
| <b>Arm title</b>             | DTG 10 mg QD |

Arm description:

Participants received DTG 10 mg, DTG matching placebo, and Abacavir/lamivudine (ABC/3TC) 600 mg/300 mg or tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg orally once daily (QD) for 96 weeks.

|                                        |                    |
|----------------------------------------|--------------------|
| Arm type                               | Experimental       |
| Investigational medicinal product name | Dolutegravir (DTG) |
| Investigational medicinal product code |                    |
| Other name                             |                    |
| Pharmaceutical forms                   | Tablet             |
| Routes of administration               | Oral use           |

Dosage and administration details:

Participants received once daily 10 milligram (mg) oral tablet in Treatment Arm A, in Treatment Arm B once daily 25 mg oral tablet and Treatment Arm C two oral tablets of 25 mg GSK1349572 once daily

|                                        |                                                                               |
|----------------------------------------|-------------------------------------------------------------------------------|
| Investigational medicinal product name | Tenofovir disoproxil fumarate /Emtricitabine (TDF/FTC) fixed dose combination |
| Investigational medicinal product code |                                                                               |
| Other name                             |                                                                               |
| Pharmaceutical forms                   | Coated tablet                                                                 |
| Routes of administration               | Oral use                                                                      |

Dosage and administration details:

Participants received a fixed dose combination tablet containing tenofovir disoproxil fumarate 300 mg and 200 mg of emtricitabine for once daily

|                                        |                                                      |
|----------------------------------------|------------------------------------------------------|
| Investigational medicinal product name | Abacavir/Lamivudine (ABC/3TC) fixed dose combination |
| Investigational medicinal product code |                                                      |
| Other name                             |                                                      |
| Pharmaceutical forms                   | Tablet                                               |
| Routes of administration               | Oral use                                             |

Dosage and administration details:

Participants received a fixed dose combination tablet containing abacavir 600 mg and 300 mg of lamivudine for once daily

|                  |              |
|------------------|--------------|
| <b>Arm title</b> | DTG 25 mg QD |
|------------------|--------------|

**Arm description:**

Participants received DTG 25 mg, DTG matching placebo, and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.

|                                        |                    |
|----------------------------------------|--------------------|
| Arm type                               | Experimental       |
| Investigational medicinal product name | Dolutegravir (DTG) |
| Investigational medicinal product code |                    |
| Other name                             |                    |
| Pharmaceutical forms                   | Tablet             |
| Routes of administration               | Oral use           |

**Dosage and administration details:**

Participants received once daily 10 milligram (mg) oral tablet in Treatment Arm A, in Treatment Arm B once daily 25 mg oral tablet and Treatment Arm C two oral tablets of 25 mg GSK1349572 once daily

|                                        |                                                      |
|----------------------------------------|------------------------------------------------------|
| Investigational medicinal product name | Abacavir/Lamivudine (ABC/3TC) fixed dose combination |
| Investigational medicinal product code |                                                      |
| Other name                             |                                                      |
| Pharmaceutical forms                   | Tablet                                               |
| Routes of administration               | Oral use                                             |

**Dosage and administration details:**

Participants received a fixed dose combination tablet containing abacavir 600 mg and 300 mg of lamivudine for once daily

|                                        |                                                                               |
|----------------------------------------|-------------------------------------------------------------------------------|
| Investigational medicinal product name | Tenofovir disoproxil fumarate /Emtricitabine (TDF/FTC) fixed dose combination |
| Investigational medicinal product code |                                                                               |
| Other name                             |                                                                               |
| Pharmaceutical forms                   | Coated tablet                                                                 |
| Routes of administration               | Oral use                                                                      |

**Dosage and administration details:**

Participants received a fixed dose combination tablet containing tenofovir disoproxil fumarate 300 mg and 200 mg of emtricitabine for once daily

|                                        |          |
|----------------------------------------|----------|
| Investigational medicinal product name | Placebo  |
| Investigational medicinal product code |          |
| Other name                             |          |
| Pharmaceutical forms                   | Tablet   |
| Routes of administration               | Oral use |

**Dosage and administration details:**

Participants received matching placebo tablets once daily along with DTG

|                  |              |
|------------------|--------------|
| <b>Arm title</b> | DTG 50 mg QD |
|------------------|--------------|

**Arm description:**

Participants received DTG 50 mg matching placebo and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.

|                                        |                    |
|----------------------------------------|--------------------|
| Arm type                               | Experimental       |
| Investigational medicinal product name | Dolutegravir (DTG) |
| Investigational medicinal product code |                    |
| Other name                             |                    |
| Pharmaceutical forms                   | Tablet             |
| Routes of administration               | Oral use           |

**Dosage and administration details:**

Participants received once daily 10 milligram (mg) oral tablet in Treatment Arm A, in Treatment Arm B once daily 25 mg oral tablet and Treatment Arm C two oral tablets of 25 mg GSK1349572 once daily

|                                        |                                                                               |
|----------------------------------------|-------------------------------------------------------------------------------|
| Investigational medicinal product name | Tenofovir disoproxil fumarate /Emtricitabine (TDF/FTC) fixed dose combination |
| Investigational medicinal product code |                                                                               |
| Other name                             |                                                                               |
| Pharmaceutical forms                   | Coated tablet                                                                 |

|                                                                                                                                                  |                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Routes of administration                                                                                                                         | Oral use                                                                      |
| Dosage and administration details:                                                                                                               |                                                                               |
| Participants received a fixed dose combination tablet containing tenofovir disoproxil fumarate 300 mg and 200 mg of emtricitabine for once daily |                                                                               |
| Investigational medicinal product name                                                                                                           | Placebo                                                                       |
| Investigational medicinal product code                                                                                                           |                                                                               |
| Other name                                                                                                                                       |                                                                               |
| Pharmaceutical forms                                                                                                                             | Tablet                                                                        |
| Routes of administration                                                                                                                         | Oral use                                                                      |
| Dosage and administration details:                                                                                                               |                                                                               |
| Participants received matching placebo tablets once daily along with DTG                                                                         |                                                                               |
| Investigational medicinal product name                                                                                                           | Abacavir/Lamivudine (ABC/3TC) fixed dose combination                          |
| Investigational medicinal product code                                                                                                           |                                                                               |
| Other name                                                                                                                                       |                                                                               |
| Pharmaceutical forms                                                                                                                             | Tablet                                                                        |
| Routes of administration                                                                                                                         | Oral use                                                                      |
| Dosage and administration details:                                                                                                               |                                                                               |
| Participants received a fixed dose combination tablet containing abacavir 600 mg and 300 mg of lamivudine for once daily                         |                                                                               |
| <b>Arm title</b>                                                                                                                                 | EFV 600 mg QD                                                                 |
| Arm description:                                                                                                                                 |                                                                               |
| Participants received Efavirenz (EFV) 600 mg and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.                          |                                                                               |
| Arm type                                                                                                                                         | Active comparator                                                             |
| Investigational medicinal product name                                                                                                           | Efavirenz (EFV)                                                               |
| Investigational medicinal product code                                                                                                           |                                                                               |
| Other name                                                                                                                                       |                                                                               |
| Pharmaceutical forms                                                                                                                             | Tablet                                                                        |
| Routes of administration                                                                                                                         | Oral use                                                                      |
| Dosage and administration details:                                                                                                               |                                                                               |
| Participants received 600 mg oral tablet of efavirenz once daily                                                                                 |                                                                               |
| Investigational medicinal product name                                                                                                           | Tenofovir disoproxil fumarate /Emtricitabine (TDF/FTC) fixed dose combination |
| Investigational medicinal product code                                                                                                           |                                                                               |
| Other name                                                                                                                                       |                                                                               |
| Pharmaceutical forms                                                                                                                             | Coated tablet                                                                 |
| Routes of administration                                                                                                                         | Oral use                                                                      |
| Dosage and administration details:                                                                                                               |                                                                               |
| Participants received a fixed dose combination tablet containing tenofovir disoproxil fumarate 300 mg and 200 mg of emtricitabine for once daily |                                                                               |
| Investigational medicinal product name                                                                                                           | Abacavir/Lamivudine (ABC/3TC) fixed dose combination                          |
| Investigational medicinal product code                                                                                                           |                                                                               |
| Other name                                                                                                                                       |                                                                               |
| Pharmaceutical forms                                                                                                                             | Tablet                                                                        |
| Routes of administration                                                                                                                         | Oral use                                                                      |
| Dosage and administration details:                                                                                                               |                                                                               |
| Participants received a fixed dose combination tablet containing abacavir 600 mg and 300 mg of lamivudine for once daily                         |                                                                               |

| Number of subjects in period 1     | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD |
|------------------------------------|--------------|--------------|--------------|
| Started                            | 53           | 51           | 51           |
| Completed                          | 48           | 44           | 46           |
| Not completed                      | 5            | 7            | 5            |
| Consent withdrawn by subject       | 2            | 1            | 1            |
| Adverse event, non-fatal           | 1            | 1            | 2            |
| Lost to follow-up                  | -            | 3            | 1            |
| Lack of efficacy                   | 1            | 1            | -            |
| Protocol deviation                 | 1            | 1            | 1            |
| Protocol-Defined Stopping Criteria | -            | -            | -            |

| Number of subjects in period 1     | EFV 600 mg QD |
|------------------------------------|---------------|
| Started                            | 50            |
| Completed                          | 40            |
| Not completed                      | 10            |
| Consent withdrawn by subject       | 2             |
| Adverse event, non-fatal           | 5             |
| Lost to follow-up                  | 2             |
| Lack of efficacy                   | -             |
| Protocol deviation                 | -             |
| Protocol-Defined Stopping Criteria | 1             |

## Period 2

|                              |                  |
|------------------------------|------------------|
| Period 2 title               | Open-label phase |
| Is this the baseline period? | No               |
| Allocation method            | Not applicable   |
| Blinding used                | Not blinded      |

## Arms

|                                                                                                                                                                      |                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| <b>Arm title</b>                                                                                                                                                     | Open-label DTG 50 mg QD |
| Arm description:                                                                                                                                                     |                         |
| All DTG participants were switched to or continued DTG 50 mg with either ABC/3TC orally at 600 mg/300 mg (1 tablet) or TDF/FTC orally QD during the Open label phase |                         |
| Arm type                                                                                                                                                             | Experimental            |
| Investigational medicinal product name                                                                                                                               | Dolutegravir (DTG)      |
| Investigational medicinal product code                                                                                                                               |                         |
| Other name                                                                                                                                                           |                         |
| Pharmaceutical forms                                                                                                                                                 | Tablet                  |
| Routes of administration                                                                                                                                             | Oral use                |

### Dosage and administration details:

Participants received once daily 10 milligram (mg) oral tablet in Treatment Arm A, in Treatment Arm B once daily 25 mg oral tablet and Treatment Arm C two oral tablets of 25 mg GSK1349572 once daily

|                                        |                                                                               |
|----------------------------------------|-------------------------------------------------------------------------------|
| Investigational medicinal product name | Tenofovir disoproxil fumarate /Emtricitabine (TDF/FTC) fixed dose combination |
| Investigational medicinal product code |                                                                               |
| Other name                             |                                                                               |
| Pharmaceutical forms                   | Coated tablet                                                                 |
| Routes of administration               | Oral use                                                                      |

Dosage and administration details:

Participants received a fixed dose combination tablet containing tenofovir disoproxil fumarate 300 mg and 200 mg of emtricitabine for once daily

|                                        |                                                      |
|----------------------------------------|------------------------------------------------------|
| Investigational medicinal product name | Abacavir/Lamivudine (ABC/3TC) fixed dose combination |
| Investigational medicinal product code |                                                      |
| Other name                             |                                                      |
| Pharmaceutical forms                   | Tablet                                               |
| Routes of administration               | Oral use                                             |

Dosage and administration details:

Participants received a fixed dose combination tablet containing abacavir 600 mg and 300 mg of lamivudine for once daily

| <b>Number of subjects in period 2</b> | Open-label DTG 50 mg QD |
|---------------------------------------|-------------------------|
| Started                               | 138                     |
| Completed                             | 88                      |
| Not completed                         | 50                      |
| Consent withdrawn by subject          | 14                      |
| Physician decision                    | 8                       |
| Adverse event, non-fatal              | 3                       |
| Lost to follow-up                     | 12                      |
| Lack of efficacy                      | 1                       |
| Protocol deviation                    | 12                      |

## Baseline characteristics

### Reporting groups

|                                                                                                                                                                                                |               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| Reporting group title                                                                                                                                                                          | DTG 10 mg QD  |
| Reporting group description:                                                                                                                                                                   |               |
| Participants received DTG 10 mg, DTG matching placebo, and Abacavir/lamivudine (ABC/3TC) 600 mg/300 mg or tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg orally once daily (QD) for 96 weeks. |               |
| Reporting group title                                                                                                                                                                          | DTG 25 mg QD  |
| Reporting group description:                                                                                                                                                                   |               |
| Participants received DTG 25 mg, DTG matching placebo, and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.                                                              |               |
| Reporting group title                                                                                                                                                                          | DTG 50 mg QD  |
| Reporting group description:                                                                                                                                                                   |               |
| Participants received DTG 50 mg matching placebo and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.                                                                    |               |
| Reporting group title                                                                                                                                                                          | EFV 600 mg QD |
| Reporting group description:                                                                                                                                                                   |               |
| Participants received Efavirenz (EFV) 600 mg and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.                                                                        |               |

| Reporting group values | DTG 10 mg QD | DTG 25 mg QD | DTG 50 mg QD |
|------------------------|--------------|--------------|--------------|
| Number of subjects     | 53           | 51           | 51           |
| Age categorical        |              |              |              |
| Units: Subjects        |              |              |              |

|                                              |        |        |        |
|----------------------------------------------|--------|--------|--------|
| Age continuous                               |        |        |        |
| Units: years                                 |        |        |        |
| arithmetic mean                              | 34.2   | 37.0   | 37.0   |
| standard deviation                           | ± 9.25 | ± 9.79 | ± 8.89 |
| Gender categorical                           |        |        |        |
| Units: Subjects                              |        |        |        |
| Female                                       | 11     | 5      | 6      |
| Male                                         | 42     | 46     | 45     |
| Race/Ethnicity, Customized                   |        |        |        |
| Units: Subjects                              |        |        |        |
| African American/African Heritage (HER)      | 7      | 6      | 8      |
| American Indian or Alaska Native             | 1      | 3      | 4      |
| Japanese/East Asian HER/South East Asian HER | 0      | 0      | 0      |
| Native Hawaiian or other Pacific Islander    | 3      | 0      | 0      |
| White                                        | 41     | 42     | 38     |
| African American/African HER & White         | 0      | 0      | 1      |
| Asian & White                                | 1      | 0      | 0      |

| Reporting group values | EFV 600 mg QD | Total |  |
|------------------------|---------------|-------|--|
| Number of subjects     | 50            | 205   |  |

|                                                                         |                 |     |  |
|-------------------------------------------------------------------------|-----------------|-----|--|
| Age categorical<br>Units: Subjects                                      |                 |     |  |
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 40.7<br>± 11.19 | -   |  |
| Gender categorical<br>Units: Subjects                                   |                 |     |  |
| Female                                                                  | 6               | 28  |  |
| Male                                                                    | 44              | 177 |  |
| Race/Ethnicity, Customized<br>Units: Subjects                           |                 |     |  |
| African American/African Heritage (HER)                                 | 4               | 25  |  |
| American Indian or Alaska Native                                        | 2               | 10  |  |
| Japanese/East Asian HER/South East Asian HER                            | 1               | 1   |  |
| Native Hawaiian or other Pacific Islander                               | 0               | 3   |  |
| White                                                                   | 43              | 164 |  |
| African American/African HER & White                                    | 0               | 1   |  |
| Asian & White                                                           | 0               | 1   |  |

### Subject analysis sets

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | Overall DTG        |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

All participants who received DTG in any DTG treatment group (DTG 10 mg QD, DTG 25 mg QD, and DTG 50 mg QD)

|                                    |             |  |  |
|------------------------------------|-------------|--|--|
| <b>Reporting group values</b>      | Overall DTG |  |  |
| Number of subjects                 | 142         |  |  |
| Age categorical<br>Units: Subjects |             |  |  |

|                                                                         |          |  |  |
|-------------------------------------------------------------------------|----------|--|--|
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 0<br>± 0 |  |  |
| Gender categorical<br>Units: Subjects                                   |          |  |  |
| Female                                                                  | 0        |  |  |
| Male                                                                    | 0        |  |  |
| Race/Ethnicity, Customized<br>Units: Subjects                           |          |  |  |
| African American/African Heritage (HER)                                 | 0        |  |  |
| American Indian or Alaska Native                                        | 0        |  |  |

|                                              |   |  |  |
|----------------------------------------------|---|--|--|
| Japanese/East Asian HER/South East Asian HER | 0 |  |  |
| Native Hawaiian or other Pacific Islander    | 0 |  |  |
| White                                        | 0 |  |  |
| African American/African HER & White         | 0 |  |  |
| Asian & White                                | 0 |  |  |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                |                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| Reporting group title                                                                                                                                                                                                          | DTG 10 mg QD            |
| Reporting group description:<br>Participants received DTG 10 mg, DTG matching placebo, and Abacavir/lamivudine (ABC/3TC) 600 mg/300 mg or tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg orally once daily (QD) for 96 weeks. |                         |
| Reporting group title                                                                                                                                                                                                          | DTG 25 mg QD            |
| Reporting group description:<br>Participants received DTG 25 mg, DTG matching placebo, and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.                                                              |                         |
| Reporting group title                                                                                                                                                                                                          | DTG 50 mg QD            |
| Reporting group description:<br>Participants received DTG 50 mg matching placebo and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.                                                                    |                         |
| Reporting group title                                                                                                                                                                                                          | EFV 600 mg QD           |
| Reporting group description:<br>Participants received Efavirenz (EFV) 600 mg and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.                                                                        |                         |
| Reporting group title                                                                                                                                                                                                          | Open-label DTG 50 mg QD |
| Reporting group description:<br>All DTG participants were switched to or continued DTG 50 mg with either ABC/3TC orally at 600 mg/300 mg (1 tablet) or TDF/FTC orally QD during the Open label phase                           |                         |
| Subject analysis set title                                                                                                                                                                                                     | Overall DTG             |
| Subject analysis set type                                                                                                                                                                                                      | Sub-group analysis      |
| Subject analysis set description:<br>All participants who received DTG in any DTG treatment group (DTG 10 mg QD, DTG 25 mg QD, and DTG 50 mg QD)                                                                               |                         |

### Primary: Number of participants with Human Immunodeficiency Virus Type 1 (HIV-1) ribonucleic acid (RNA) <50 copies/milliliter (c/mL) at Week 16

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Number of participants with Human Immunodeficiency Virus Type 1 (HIV-1) ribonucleic acid (RNA) <50 copies/milliliter (c/mL) at Week 16 <sup>[1]</sup> |
| End point description:<br>Plasma samples were collected for quantitative HIV-1 RNA analysis at Week 16. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (<50 copies/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason. Data are reported per the Week 16 report. In later cuts of the data, the Week 16 values may have changed (because of the nature of the TLOVR algorithm).ITT-E Population included all randomized participants who received at least one dose of study medication |                                                                                                                                                       |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Primary                                                                                                                                               |
| End point timeframe:<br>Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                       |

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

| End point values            | DTG 10 mg QD      | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD   |
|-----------------------------|-------------------|-----------------|-----------------|-----------------|
| Subject group type          | Reporting group   | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 53 <sup>[2]</sup> | 51              | 51              | 50              |
| Units: participants         |                   |                 |                 |                 |
| participants                | 51                | 47              | 46              | 29              |

Notes:

[2] - ITT-E Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Viral change over the initial 2 weeks of treatment

|                 |                                                    |
|-----------------|----------------------------------------------------|
| End point title | Viral change over the initial 2 weeks of treatment |
|-----------------|----------------------------------------------------|

End point description:

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline and Week 2. Viral change is defined as the change in plasma HIV-1 RNA over the initial 2 weeks of treatment, calculated as the value at Week 2 minus the value at Baseline. Only those participants available at the specified time point were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 2

| End point values                     | DTG 10 mg QD      | DTG 25 mg QD      | DTG 50 mg QD      | EFV 600 mg QD     |
|--------------------------------------|-------------------|-------------------|-------------------|-------------------|
| Subject group type                   | Reporting group   | Reporting group   | Reporting group   | Reporting group   |
| Number of subjects analysed          | 53 <sup>[3]</sup> | 50                | 50                | 48                |
| Units: Log10 c/mL                    |                   |                   |                   |                   |
| arithmetic mean (standard deviation) |                   |                   |                   |                   |
| Log10 c/mL                           | -2.387 (± 0.4595) | -2.365 (± 0.5458) | -2.392 (± 0.4241) | -1.930 (± 0.4312) |

Notes:

[3] - ITT-E Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in HIV-1 RNA at the indicated time points

|                 |                                                                |
|-----------------|----------------------------------------------------------------|
| End point title | Change from Baseline in HIV-1 RNA at the indicated time points |
|-----------------|----------------------------------------------------------------|

End point description:

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96

| End point values                     | DTG 10 mg QD      | DTG 25 mg QD      | DTG 50 mg QD      | EFV 600 mg QD     |
|--------------------------------------|-------------------|-------------------|-------------------|-------------------|
| Subject group type                   | Reporting group   | Reporting group   | Reporting group   | Reporting group   |
| Number of subjects analysed          | 53 <sup>[4]</sup> | 51                | 51                | 50                |
| Units: Log <sub>10</sub> c/mL        |                   |                   |                   |                   |
| arithmetic mean (standard deviation) |                   |                   |                   |                   |
| Week 1, n=53, 50, 48, 50             | -1.815 (± 0.3999) | -1.773 (± 0.4650) | -1.738 (± 0.3840) | -1.562 (± 0.4158) |
| Week 2, n=53, 50, 50, 48             | -2.387 (± 0.4595) | -2.365 (± 0.5458) | -2.392 (± 0.4241) | -1.930 (± 0.4312) |
| Week 4, n=53, 50, 50, 45             | -2.629 (± 0.5863) | -2.583 (± 0.6337) | -2.713 (± 0.5471) | -2.162 (± 0.5400) |
| Week 8, n=52, 50, 49, 45             | -2.657 (± 0.6980) | -2.666 (± 0.6667) | -2.848 (± 0.6556) | -2.450 (± 0.5989) |
| Week 12, n=53, 49, 49, 45            | -2.685 (± 0.6831) | -2.671 (± 0.6850) | -2.860 (± 0.6772) | -2.603 (± 0.5869) |
| Week 16, n=52, 49, 49, 45            | -2.718 (± 0.6593) | -2.668 (± 0.6826) | -2.859 (± 0.6876) | -2.698 (± 0.6715) |
| Week 20, n=52, 48, 49, 44            | -2.701 (± 0.6423) | -2.662 (± 0.6908) | -2.869 (± 0.6896) | -2.745 (± 0.6602) |
| Week 24, n=52, 49, 48, 45            | -2.700 (± 0.6261) | -2.657 (± 0.6969) | -2.853 (± 0.6889) | -2.773 (± 0.7026) |
| Week 32, n=52, 49, 47, 45            | -2.717 (± 0.6588) | -2.658 (± 0.6991) | -2.855 (± 0.6963) | -2.772 (± 0.7021) |
| Week 40, n=51, 48, 47, 44            | -2.647 (± 0.7039) | -2.665 (± 0.7051) | -2.855 (± 0.6934) | -2.795 (± 0.7169) |
| Week 48, n=51, 48, 48, 45            | -2.723 (± 0.6519) | -2.667 (± 0.6934) | -2.850 (± 0.6849) | -2.711 (± 0.7765) |
| Week 60, n=50, 48, 48, 44            | -2.741 (± 0.6444) | -2.675 (± 0.7012) | -2.825 (± 0.7458) | -2.765 (± 0.7035) |
| Week 72, n=51, 47, 48, 44            | -2.742 (± 0.6453) | -2.622 (± 0.8052) | -2.860 (± 0.6930) | -2.757 (± 0.7094) |
| Week 84, n=51, 47, 47, 43            | -2.725 (± 0.6506) | -2.670 (± 0.7064) | -2.855 (± 0.6923) | -2.743 (± 0.7321) |
| Week 96, n=48, 44, 46, 39            | -2.728 (± 0.6494) | -2.680 (± 0.7116) | -2.854 (± 0.7061) | -2.807 (± 0.7238) |

Notes:

[4] - ITT-E Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in cluster of differentiation 4+ (CD4+) cell counts at the indicated time points

|                 |                                                                                                       |
|-----------------|-------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline in cluster of differentiation 4+ (CD4+) cell counts at the indicated time points |
|-----------------|-------------------------------------------------------------------------------------------------------|

End point description:

Blood samples were collected for lymphocyte subset assessment by flow cytometry at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT-E Population.

|                                                                                                                                                         |           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| End point type                                                                                                                                          | Secondary |
| End point timeframe:                                                                                                                                    |           |
| Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96 |           |

| End point values                      | DTG 10 mg QD           | DTG 25 mg QD           | DTG 50 mg QD           | EFV 600 mg QD          |
|---------------------------------------|------------------------|------------------------|------------------------|------------------------|
| Subject group type                    | Reporting group        | Reporting group        | Reporting group        | Reporting group        |
| Number of subjects analysed           | 53 <sup>[5]</sup>      | 51                     | 51                     | 50                     |
| Units: Cells per cubic millimeter     |                        |                        |                        |                        |
| median (inter-quartile range (Q1-Q3)) |                        |                        |                        |                        |
| Week 1, n=53, 50, 48, 50              | 85.0 (18.0 to 134.0)   | 94.5 (40.0 to 160.0)   | 75.5 (18.5 to 129.5)   | 42.5 (-23.0 to 111.0)  |
| Week 2, n=53, 50, 50, 47              | 75.0 (37.0 to 124.0)   | 79.0 (27.0 to 138.0)   | 99.5 (53.0 to 160.0)   | 55.0 (-10.0 to 132.0)  |
| Week 4, n=53, 50, 50, 45              | 75.0 (34.0 to 151.0)   | 89.0 (36.0 to 165.0)   | 110.0 (46.0 to 170.0)  | 89.0 (30.0 to 165.0)   |
| Week 8, n=52, 50, 49, 44              | 118.5 (65.5 to 210.5)  | 156.5 (93.0 to 226.0)  | 129.0 (105.0 to 201.0) | 104.5 (34.5 to 240.5)  |
| Week 12, n=53, 48, 48, 45             | 139.0 (96.0 to 284.0)  | 137.5 (61.0 to 250.0)  | 171.5 (107.5 to 269.0) | 127.0 (58.0 to 186.0)  |
| Week 16, n=52, 49, 49, 44             | 153.0 (95.0 to 276.0)  | 176.0 (86.0 to 227.0)  | 160.0 (94.0 to 227.0)  | 115.5 (65.5 to 226.0)  |
| Week 20, n=52, 48, 49, 44             | 163.5 (79.5 to 288.5)  | 200.0 (103.0 to 316.5) | 139.0 (64.0 to 238.0)  | 136.0 (54.5 to 215.5)  |
| Week 24, n=51, 49, 47, 44             | 159.0 (97.0 to 233.0)  | 206.0 (102.0 to 289.0) | 167.0 (125.0 to 268.0) | 109.5 (66.0 to 229.0)  |
| Week 32, n=50, 48, 47, 44             | 221.5 (94.0 to 300.0)  | 195.5 (109.0 to 294.0) | 203.0 (125.0 to 282.0) | 146.5 (82.5 to 223.5)  |
| Week 40, n=50, 48, 47, 44             | 205.0 (136.0 to 364.0) | 204.5 (157.5 to 346.5) | 224.0 (123.0 to 322.0) | 171.5 (123.0 to 268.0) |
| Week 48, n=51, 47, 47, 45             | 204.0 (127.0 to 384.0) | 249.0 (143.0 to 416.0) | 223.0 (141.0 to 292.0) | 174.0 (91.0 to 292.0)  |
| Week 60, n=51, 48, 47, 43             | 265.0 (173.0 to 365.0) | 278.0 (198.5 to 369.5) | 229.0 (166.0 to 306.0) | 221.0 (153.0 to 355.0) |
| Week 72, n=51, 47, 48, 44             | 236.0 (177.0 to 351.0) | 285.0 (186.0 to 427.0) | 220.0 (146.0 to 373.0) | 195.0 (144.0 to 334.5) |
| Week 84, n=51, 47, 46, 42             | 292.0 (222.0 to 408.0) | 313.0 (244.0 to 366.0) | 280.0 (197.0 to 379.0) | 296.5 (187.0 to 400.0) |
| Week 96, n=48, 44, 46, 39             | 335.0 (253.5 to 478.5) | 391.5 (243.0 to 527.0) | 326.0 (236.0 to 451.0) | 301.0 (204.0 to 445.0) |

Notes:

[5] - ITT-E Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with new HIV-associated conditions of the indicated class

|                 |                                                                                  |
|-----------------|----------------------------------------------------------------------------------|
| End point title | Number of participants with new HIV-associated conditions of the indicated class |
|-----------------|----------------------------------------------------------------------------------|

End point description:

HIV-associated conditions were assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON),

without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the acquired immunodeficiency syndrome (AIDS) surveillance case definition.

|                             |           |
|-----------------------------|-----------|
| End point type              | Secondary |
| End point timeframe:        |           |
| From Baseline up to Week 96 |           |

| End point values            | DTG 10 mg QD      | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD   |
|-----------------------------|-------------------|-----------------|-----------------|-----------------|
| Subject group type          | Reporting group   | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 53 <sup>[6]</sup> | 51              | 51              | 50              |
| Units: Participants         |                   |                 |                 |                 |
| Category B                  | 2                 | 0               | 1               | 1               |
| Category C                  | 0                 | 0               | 1               | 0               |
| Death                       | 1                 | 0               | 0               | 0               |

Notes:

[6] - ITT-E Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with the indicated type of HIV-1 disease progression (AIDS or death)

|                 |                                                                                             |
|-----------------|---------------------------------------------------------------------------------------------|
| End point title | Number of participants with the indicated type of HIV-1 disease progression (AIDS or death) |
|-----------------|---------------------------------------------------------------------------------------------|

End point description:

Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CAT A at Baseline (BS) to CAT B event (EV), CAT A at BS to a CAT C EV; CAT B at BS to a CAT C EV; CAT C at BS to a new CAT C EV; or CAT A, B, or C at BS to death.

|                             |           |
|-----------------------------|-----------|
| End point type              | Secondary |
| End point timeframe:        |           |
| From Baseline up to Week 96 |           |

| End point values                       | DTG 10 mg QD      | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD   |
|----------------------------------------|-------------------|-----------------|-----------------|-----------------|
| Subject group type                     | Reporting group   | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed            | 53 <sup>[7]</sup> | 51              | 51              | 50              |
| Units: Participants                    |                   |                 |                 |                 |
| CAT A at Baseline to a CAT C event     | 0                 | 0               | 0               | 0               |
| CAT B at Baseline to a CAT C event     | 0                 | 0               | 1               | 0               |
| CAT C at Baseline to a new CAT C event | 0                 | 0               | 0               | 0               |
| CAT A, B, or C at Baseline to death    | 1                 | 0               | 0               | 0               |

Notes:

[7] - ITT-E Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with plasma HIV-1 RNA <50 c/mL

|                 |                                                       |
|-----------------|-------------------------------------------------------|
| End point title | Number of participants with plasma HIV-1 RNA <50 c/mL |
|-----------------|-------------------------------------------------------|

End point description:

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (<50 copies/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96

| End point values            | DTG 10 mg QD      | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD   |
|-----------------------------|-------------------|-----------------|-----------------|-----------------|
| Subject group type          | Reporting group   | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 53 <sup>[8]</sup> | 51              | 51              | 50              |
| Units: Participants         |                   |                 |                 |                 |
| Baseline                    | 0                 | 0               | 0               | 0               |
| Week 1                      | 6                 | 4               | 4               | 3               |
| Week 2                      | 22                | 19              | 11              | 6               |
| Week 4                      | 37                | 35              | 31              | 9               |
| Week 8                      | 46                | 45              | 43              | 18              |
| Week 12                     | 50                | 46              | 45              | 25              |
| Week 16                     | 51                | 46              | 47              | 29              |
| Week 20                     | 51                | 47              | 47              | 38              |
| Week 24                     | 51                | 46              | 47              | 41              |
| Week 32                     | 50                | 45              | 46              | 43              |
| Week 40                     | 49                | 45              | 46              | 42              |
| Week 48                     | 48                | 45              | 46              | 40              |
| Week 60                     | 48                | 44              | 46              | 41              |

|         |    |    |    |    |
|---------|----|----|----|----|
| Week 72 | 48 | 44 | 45 | 40 |
| Week 84 | 47 | 43 | 46 | 38 |
| Week 96 | 42 | 40 | 45 | 36 |

Notes:

[8] - ITT-E Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with plasma HIV-1 RNA <400 c/mL

|                 |                                                        |
|-----------------|--------------------------------------------------------|
| End point title | Number of participants with plasma HIV-1 RNA <400 c/mL |
|-----------------|--------------------------------------------------------|

End point description:

Plasma samples were collected for quantitative HIV-1 RNA analysis at Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96. The analysis was performed using the time to loss of virological response (TLOVR) dataset. In the TLOVR dataset, participant responses at a specified threshold of HIV-1 RNA (<400 c/mL) are determined by using the Food and Drug Administration's TLOVR algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96

| End point values            | DTG 10 mg QD      | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD   |
|-----------------------------|-------------------|-----------------|-----------------|-----------------|
| Subject group type          | Reporting group   | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 53 <sup>[9]</sup> | 51              | 51              | 50              |
| Units: Participants         |                   |                 |                 |                 |
| Baseline                    | 0                 | 0               | 0               | 0               |
| Week 1                      | 25                | 20              | 16              | 15              |
| Week 2                      | 45                | 45              | 41              | 23              |
| Week 4                      | 52                | 49              | 48              | 32              |
| Week 8                      | 52                | 49              | 49              | 41              |
| Week 12                     | 52                | 49              | 49              | 45              |
| Week 16                     | 52                | 48              | 49              | 45              |
| Week 20                     | 52                | 48              | 49              | 45              |
| Week 24                     | 52                | 47              | 48              | 45              |
| Week 32                     | 52                | 47              | 48              | 45              |
| Week 40                     | 50                | 47              | 48              | 45              |
| Week 48                     | 50                | 47              | 48              | 44              |
| Week 60                     | 50                | 46              | 48              | 44              |
| Week 72                     | 50                | 46              | 47              | 43              |
| Week 84                     | 50                | 45              | 47              | 42              |
| Week 96                     | 46                | 43              | 46              | 39              |

Notes:

[9] - ITT-E Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with any adverse event (AE) and any serious adverse events (SAE)

|                 |                                                                                         |
|-----------------|-----------------------------------------------------------------------------------------|
| End point title | Number of participants with any adverse event (AE) and any serious adverse events (SAE) |
|-----------------|-----------------------------------------------------------------------------------------|

End point description:

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity; or is a congenital anomaly/birth defect. All clinically suspected cases of hypersensitivity reaction to abacavir in participants receiving abacavir/lamivudine were reported as SAEs. Medical or scientific judgment was to have been exercised in other situations. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold  $\geq 3\%$ ) and SAEs.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Baseline up to Week 96/Early Withdrawal

| End point values            | DTG 10 mg QD       | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD   |
|-----------------------------|--------------------|-----------------|-----------------|-----------------|
| Subject group type          | Reporting group    | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 53 <sup>[10]</sup> | 51              | 51              | 50              |
| Units: Participants         |                    |                 |                 |                 |
| Any AE                      | 50                 | 46              | 46              | 46              |
| Any SAE                     | 5                  | 5               | 7               | 7               |

Notes:

[10] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with the indicated Grade 1 to Grade 4 treatment-emergent clinical chemistry and hematology toxicities

|                 |                                                                                                                              |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with the indicated Grade 1 to Grade 4 treatment-emergent clinical chemistry and hematology toxicities |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|

End point description:

Blood samples were collected for the measurement of clinical chemistry and hematology parameters. Toxicities were graded for severity according to the Division of AIDS (DAIDS) toxicity scales as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (potentially life threatening).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Baseline up to Week 96/Early Withdrawal

| End point values                      | DTG 10 mg QD       | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD   |
|---------------------------------------|--------------------|-----------------|-----------------|-----------------|
| Subject group type                    | Reporting group    | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed           | 53 <sup>[11]</sup> | 51              | 51              | 50              |
| Units: Participants                   |                    |                 |                 |                 |
| Alanine amino transferase             | 7                  | 11              | 3               | 19              |
| Cholesterol                           | 18                 | 16              | 13              | 24              |
| Creatinine kinase                     | 17                 | 6               | 7               | 5               |
| Lipase                                | 11                 | 13              | 11              | 9               |
| Triglycerides                         | 0                  | 1               | 2               | 1               |
| Alkaline phosphatase                  | 1                  | 0               | 1               | 10              |
| Amylase                               | 2                  | 3               | 1               | 4               |
| Aspartate amino transferase           | 12                 | 8               | 6               | 9               |
| Carbon dioxide content/bicarbonate    | 28                 | 24              | 23              | 30              |
| Creatinine                            | 0                  | 4               | 0               | 0               |
| Hypercalcemia                         | 0                  | 0               | 0               | 1               |
| Hyperglycaemia                        | 16                 | 15              | 17              | 17              |
| Hyperkalemia                          | 0                  | 0               | 1               | 1               |
| Hypernatremia                         | 1                  | 1               | 1               | 0               |
| Hypocalcemia                          | 4                  | 5               | 5               | 8               |
| Hypoglycaemia                         | 3                  | 3               | 5               | 4               |
| Hypokalemia                           | 4                  | 1               | 3               | 3               |
| Hyponatremia                          | 6                  | 12              | 7               | 13              |
| Low-density lipoprotein cholesterol   | 14                 | 15              | 11              | 20              |
| Magnesium                             | 7                  | 6               | 5               | 4               |
| Phosphate, inorganic                  | 9                  | 15              | 14              | 11              |
| Total bilirubin                       | 3                  | 4               | 3               | 0               |
| Activated partial thromboplastin time | 7                  | 12              | 6               | 5               |
| Hemoglobin                            | 0                  | 1               | 0               | 1               |
| International normalized ratio        | 6                  | 9               | 6               | 5               |
| Platelet count                        | 1                  | 4               | 1               | 1               |
| Prothrombin time                      | 7                  | 8               | 7               | 4               |
| Total neutrophils                     | 9                  | 7               | 6               | 10              |
| White blood cell count                | 1                  | 1               | 1               | 1               |

Notes:

[11] - Safety Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with the indicated treatment-emergent integrase (IN) mutations detected at the time of protocol-defined virologic failure (PDVF), as a measure of genotypic resistance

|                 |                                                                                                                                                                                    |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with the indicated treatment-emergent integrase (IN) mutations detected at the time of protocol-defined virologic failure (PDVF), as a measure of genotypic |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## End point description:

For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of  $<1$  log<sub>10</sub> copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is  $<400$  copies/mL; confirmed plasma HIV-1 RNA levels  $\geq 400$  copies/mL on or after Week 24 without evidence of prior suppression to  $<400$  copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to  $\geq 400$  copies/mL after prior confirmed suppression to  $<400$  copies/mL; confirmed plasma HIV-1 RNA levels  $>0.5$  log<sub>10</sub> copies/mL above the nadir value, where nadir is the lowest HIV-1 value  $\geq 400$  copies/mL. On-treatment Genotypic Resistance Population: all participants in the ITT-E Population with available on-treatment genotypic data, excluding participants who were not protocol-defined virologic failures.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

From Baseline up to Week 96/Early Withdrawal

| End point values            | DTG 10 mg QD    | DTG 25 mg QD    | DTG 50 mg QD      | EFV 600 mg QD   |
|-----------------------------|-----------------|-----------------|-------------------|-----------------|
| Subject group type          | Reporting group | Reporting group | Reporting group   | Reporting group |
| Number of subjects analysed | 2               | 1               | 0 <sup>[12]</sup> | 1               |
| Units: Participants         |                 |                 |                   |                 |
| A23A/V                      | 1               | 0               |                   | 0               |
| S255N                       | 1               | 0               |                   | 0               |

Notes:

[12] - On-treatment Genotypic Resistance Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with the indicated treatment-emergent major mutations of other classes detected at the time of protocol-defined virologic failure (PDVF), as a measure of genotypic resistance

|                 |                                                                                                                                                                                                       |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with the indicated treatment-emergent major mutations of other classes detected at the time of protocol-defined virologic failure (PDVF), as a measure of genotypic resistance |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## End point description:

For participants meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of  $<1$  log<sub>10</sub> copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is  $<400$  copies/mL; confirmed plasma HIV-1 RNA levels  $\geq 400$  copies/mL on or after Week 24 without evidence of prior suppression to  $<400$  copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to  $\geq 400$  copies/mL after prior confirmed suppression to  $<400$  copies/mL; confirmed plasma HIV-1 RNA levels  $>0.5$  log<sub>10</sub> copies/mL above the nadir value, where nadir is the lowest HIV-1 value  $\geq 400$  copies/mL.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

From Baseline up to Week 96/Early Withdrawal

| End point values            | DTG 10 mg QD    | DTG 25 mg QD    | DTG 50 mg QD      | EFV 600 mg QD   |
|-----------------------------|-----------------|-----------------|-------------------|-----------------|
| Subject group type          | Reporting group | Reporting group | Reporting group   | Reporting group |
| Number of subjects analysed | 2               | 1               | 0 <sup>[13]</sup> | 1               |
| Units: Participants         |                 |                 |                   |                 |
| Participants                | 1               | 0               |                   | 0               |

Notes:

[13] - On-treatment Genotypic Resistance Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with the indicated fold increase in DTG FC (fold change in IC50 relative to wild-type virus) at the time of PDVF, as a measure of post-Baseline phenotypic resistance

|                 |                                                                                                                                                                                              |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with the indicated fold increase in DTG FC (fold change in IC50 relative to wild-type virus) at the time of PDVF, as a measure of post-Baseline phenotypic resistance |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF. Fold increase in DTG FC at the time of PDVF was derived as the PDVF FC/Baseline FC ratio. PDVF was defined as (A) Virologic Non-response: a decrease in plasma HIV-1 RNA of <1 log10 copies/mL by Week 4, with subsequent confirmation, unless plasma HIV-1 RNA is <400 copies/mL; confirmed plasma HIV-1 RNA levels ≥400 copies/mL on or after Week 24 without evidence of prior suppression to <400copies/mL or (B) Virologic Rebound: confirmed rebound in plasma HIV-1 RNA levels to ≥400 copies/mL after prior confirmed suppression to <400 copies/mL; confirmed plasma HIV-1 RNA levels >0.5 log10 copies/mL above the nadir value, where nadir is the lowest HIV-1 value ≥400 copies/mL. On-treatment Phenotypic Resistance Population: all participants in the ITT-E Population with available on-treatment phenotypic data

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Baseline up to Week 96/Early Withdrawal

| End point values            | DTG 10 mg QD    | DTG 25 mg QD    | DTG 50 mg QD      | EFV 600 mg QD     |
|-----------------------------|-----------------|-----------------|-------------------|-------------------|
| Subject group type          | Reporting group | Reporting group | Reporting group   | Reporting group   |
| Number of subjects analysed | 2               | 1               | 0 <sup>[14]</sup> | 0 <sup>[15]</sup> |
| Units: Participants         |                 |                 |                   |                   |
| <1 fold                     | 0               | 1               |                   |                   |
| 1-<2 fold                   | 2               | 0               |                   |                   |
| 2-<4 fold                   | 0               | 0               |                   |                   |
| 4-<8 fold                   | 0               | 0               |                   |                   |
| ≥8 fold                     | 0               | 0               |                   |                   |

Notes:

[14] - On-treatment Phenotypic Resistance Population

[15] - On-treatment Phenotypic Resistance Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Plasma DTG concentration

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Plasma DTG concentration |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                          |
| Blood samples for the determination of plasma DTG concentration were collected from the participants randomized to receive DTG, at the following time points: pre-dose and 2-4 hours post-dose at Weeks 2, Week 12, and Week 24. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. The Pharmacokinetic (PK) Summary Population is comprised of all participants who received DTG and underwent intensive PK sampling or limited PK sampling during the study and provided evaluable DTG PK parameters. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the PK Summary Population. |                          |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Secondary                |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| Week 2, Week 12, and Week 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                          |

| End point values                              | DTG 10 mg QD       | DTG 25 mg QD       | DTG 50 mg QD       | EFV 600 mg QD     |
|-----------------------------------------------|--------------------|--------------------|--------------------|-------------------|
| Subject group type                            | Reporting group    | Reporting group    | Reporting group    | Reporting group   |
| Number of subjects analysed                   | 48                 | 46                 | 46                 | 0 <sup>[16]</sup> |
| Units: Micrograms per milliliter (µg/mL)      |                    |                    |                    |                   |
| arithmetic mean (standard deviation)          |                    |                    |                    |                   |
| Week 2, Pre-dose, n=46, 44, 43, 0             | 0.3580 (± 0.18321) | 0.6779 (± 0.44085) | 1.4044 (± 0.88041) | ()                |
| Week 2, 2-4 hours post-dose, n=31, 29, 29, 0  | 1.0121 (± 0.28125) | 1.9716 (± 0.71890) | 3.8414 (± 1.87405) | ()                |
| Week 12, Pre-dose, n= 46, 45, 44, 0           | 0.3648 (± 0.16791) | 0.5759 (± 0.32645) | 1.4169 (± 1.00152) | ()                |
| Week 12, 2-4 hours post-dose, n=48, 45, 45, 0 | 1.0374 (± 0.27517) | 1.7907 (± 0.70953) | 3.6056 (± 1.33862) | ()                |
| Week 24, Pre-dose, n=45, 44, 44, 0            | 0.3766 (± 0.23399) | 0.6636 (± 0.50767) | 1.4534 (± 0.94283) | ()                |
| Week 24, 2-4 hours post-dose, n=45, 45, 45, 0 | 1.0113 (± 0.34083) | 1.9021 (± 0.79430) | 3.5397 (± 1.36538) | ()                |

Notes:

[16] - PK Summary Population.

## Statistical analyses

No statistical analyses for this end point

## Secondary: AUC(0-tau) of DTG

|                                                                                                                                                                                                                                                                                                                                                                                                                                        |                   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                        | AUC(0-tau) of DTG |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                 |                   |
| The area under the time concentration curve over the dosing interval (AUC[0-tau]) of DTG was determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed. |                   |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                         | Secondary         |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                   |                   |
| Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2                                                                                                                                                                                                                                                                                                                                                                              |                   |

| End point values                                    | DTG 10 mg QD    | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD     |
|-----------------------------------------------------|-----------------|-----------------|-----------------|-------------------|
| Subject group type                                  | Reporting group | Reporting group | Reporting group | Reporting group   |
| Number of subjects analysed                         | 15              | 15              | 15              | 0 <sup>[17]</sup> |
| Units: Hours*µg/mL                                  |                 |                 |                 |                   |
| geometric mean (geometric coefficient of variation) |                 |                 |                 |                   |
| Hours*µg/mL                                         | 16.0 (± 40)     | 23.1 (± 48)     | 48.1 (± 40)     | ()                |

Notes:

[17] - PK Summary Population.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Maximal concentration (C<sub>max</sub>), minimal concentration (C<sub>min</sub>), and concentration at the end of dosing interval (C<sub>tau</sub>) of DTG

|                 |                                                                                                                                                                  |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Maximal concentration (C <sub>max</sub> ), minimal concentration (C <sub>min</sub> ), and concentration at the end of dosing interval (C <sub>tau</sub> ) of DTG |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

The C<sub>max</sub>, C<sub>min</sub>, and C<sub>tau</sub> of DTG were determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2

| End point values                                    | DTG 10 mg QD    | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD     |
|-----------------------------------------------------|-----------------|-----------------|-----------------|-------------------|
| Subject group type                                  | Reporting group | Reporting group | Reporting group | Reporting group   |
| Number of subjects analysed                         | 15              | 15              | 15              | 0 <sup>[18]</sup> |
| Units: µg/mL                                        |                 |                 |                 |                   |
| geometric mean (geometric coefficient of variation) |                 |                 |                 |                   |
| C <sub>max</sub>                                    | 1.10 (± 37)     | 1.71 (± 43)     | 3.40 (± 27)     | ()                |
| C <sub>min</sub>                                    | 0.33 (± 64)     | 0.44 (± 68)     | 0.94 (± 74)     | ()                |
| C <sub>tau</sub>                                    | 0.37 (± 55)     | 0.45 (± 71)     | 1.05 (± 72)     | ()                |

Notes:

[18] - PK Summary Population.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pre-dose concentration (C<sub>0</sub>) and C<sub>0</sub> avg of DTG

|                 |                                                                        |
|-----------------|------------------------------------------------------------------------|
| End point title | Pre-dose concentration (C <sub>0</sub> ) and C <sub>0</sub> avg of DTG |
|-----------------|------------------------------------------------------------------------|

End point description:

The plasma DTG C0 of DTG was determined using limited/sparse PK sampling at Week 2, Week 12, and Week 24. C0 avg was calculated at Week 24 as the mean of the C0 of DTG at Week 2, Week 12, and Week 24. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the PK Summary Population.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 2, Week 12, and Week 24

| End point values                                    | DTG 10 mg QD    | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD     |
|-----------------------------------------------------|-----------------|-----------------|-----------------|-------------------|
| Subject group type                                  | Reporting group | Reporting group | Reporting group | Reporting group   |
| Number of subjects analysed                         | 49              | 46              | 46              | 0 <sup>[19]</sup> |
| Units: Microgram per milliliter (µg/mL)             |                 |                 |                 |                   |
| geometric mean (geometric coefficient of variation) |                 |                 |                 |                   |
| C0, Week 2, n=46, 44, 43, 0                         | 0.31 (± 58)     | 0.57 (± 62)     | 1.20 (± 61)     | ()                |
| C0, Week 12, n=46, 45, 44, 0                        | 0.33 (± 49)     | 0.47 (± 77)     | 1.13 (± 95)     | ()                |
| C0, Week 24, n=45, 44, 44, 0                        | 0.33 (± 67)     | 0.57 (± 74)     | 1.20 (± 74)     | ()                |
| C0 avg, n=48, 46, 46, 0                             | 0.34 (± 49)     | 0.56 (± 61)     | 1.25 (± 55)     | ()                |

Notes:

[19] - PK Summary Population.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to maximal drug concentration (tmax) of DTG

|                 |                                                  |
|-----------------|--------------------------------------------------|
| End point title | Time to maximal drug concentration (tmax) of DTG |
|-----------------|--------------------------------------------------|

End point description:

Tmax of DTG was determined using non-compartmental analysis based on intensive PK sampling at the following time points: pre-dose; 2, 3, 4, 8, and 24 hours post-dose at Week 2. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-dose and 2, 3, 4, 8, and 24 hours post-dose at Week 2

| End point values              | DTG 10 mg QD     | DTG 25 mg QD     | DTG 50 mg QD     | EFV 600 mg QD     |
|-------------------------------|------------------|------------------|------------------|-------------------|
| Subject group type            | Reporting group  | Reporting group  | Reporting group  | Reporting group   |
| Number of subjects analysed   | 15               | 15               | 15               | 0 <sup>[20]</sup> |
| Units: Hours                  |                  |                  |                  |                   |
| median (full range (min-max)) |                  |                  |                  |                   |
| Hours                         | 2.0 (2.0 to 4.0) | 2.0 (2.0 to 8.0) | 2.0 (1.9 to 4.0) | ( to )            |

Notes:

[20] - PK Summary Population.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Relationship between the change from Baseline in plasma HIV-1 RNA at Week 2 and the indicated plasma DTG PK parameters

|                 |                                                                                                                        |
|-----------------|------------------------------------------------------------------------------------------------------------------------|
| End point title | Relationship between the change from Baseline in plasma HIV-1 RNA at Week 2 and the indicated plasma DTG PK parameters |
|-----------------|------------------------------------------------------------------------------------------------------------------------|

End point description:

Relationships between Week 2 plasma DTG PK parameters (AUC[0-tau] [area under the time concentration curve over the dosing interval], Cmax [maximal concentration], and Ctau [concentration at the end of the dosing interval]) and the change from Baseline in plasma HIV-1 RNA at Week 2 (calculated as the post-Baseline value minus the value at Baseline) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between plasma HIV-1 RNA and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. PK/Pharmacodynamic (PD) Analysis Population: all participants with available PD measures (e.g., safety and/or efficacy data) and with evaluable DTG plasma concentration data considered suitable for investigation of relationship with the PD measures

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 2

| End point values                         | DTG 10 mg QD    | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD     |
|------------------------------------------|-----------------|-----------------|-----------------|-------------------|
| Subject group type                       | Reporting group | Reporting group | Reporting group | Reporting group   |
| Number of subjects analysed              | 15              | 15              | 15              | 0 <sup>[21]</sup> |
| Units: Pearson's correlation coefficient |                 |                 |                 |                   |
| number (not applicable)                  |                 |                 |                 |                   |
| AUC(0-tau)                               | 0.426           | -0.018          | -0.258          |                   |
| Cmax                                     | 0.452           | -0.051          | -0.150          |                   |
| Ctau                                     | 0.273           | -0.100          | -0.263          |                   |

Notes:

[21] - PK/PD Analysis Population.

| End point values                         | Overall DTG          |  |  |  |
|------------------------------------------|----------------------|--|--|--|
| Subject group type                       | Subject analysis set |  |  |  |
| Number of subjects analysed              | 45                   |  |  |  |
| Units: Pearson's correlation coefficient |                      |  |  |  |
| number (not applicable)                  |                      |  |  |  |
| AUC(0-tau)                               | -0.086               |  |  |  |
| Cmax                                     | -0.055               |  |  |  |
| Ctau                                     | -0.129               |  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Relationship between the change from Baseline in CD4+ cell counts at Week 96 and the indicated plasma DTG PK parameters

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Relationship between the change from Baseline in CD4+ cell counts at Week 96 and the indicated plasma DTG PK parameters |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                         |
| Relationships between plasma DTG PK parameters (AUC[0-tau] [area under the time concentration curve over the dosing interval], Cmax [maximal concentration], C0avg [average pre-dose concentration], and Ctau [concentration at the end of the dosing interval]) and the change from Baseline in CD4+ cell counts at Week 96 (calculated as the post-Baseline value minus the value at Baseline) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between CD4+ cell counts and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles) |                                                                                                                         |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Secondary                                                                                                               |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                         |
| Week 96                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                         |

| End point values                         | DTG 10 mg QD    | DTG 25 mg QD    | DTG 50 mg QD    | EFV 600 mg QD     |
|------------------------------------------|-----------------|-----------------|-----------------|-------------------|
| Subject group type                       | Reporting group | Reporting group | Reporting group | Reporting group   |
| Number of subjects analysed              | 50              | 46              | 46              | 0 <sup>[22]</sup> |
| Units: Pearson's correlation coefficient |                 |                 |                 |                   |
| number (not applicable)                  |                 |                 |                 |                   |
| AUC(0-tau), n=13, 14, 15, 0              | -0.100          | 0.379           | 0.008           |                   |
| Cmax, n=13, 14, 15, 0                    | -0.047          | 0.332           | 0.234           |                   |
| C0avg, n=43, 40, 42, 0                   | -0.009          | -0.013          | 0.206           |                   |
| Ctau, n=13, 14, 15, 0                    | -0.289          | 0.299           | -0.074          |                   |

Notes:

[22] - PK/PD Analysis Population.

| End point values                         | Overall DTG          |  |  |  |
|------------------------------------------|----------------------|--|--|--|
| Subject group type                       | Subject analysis set |  |  |  |
| Number of subjects analysed              | 142                  |  |  |  |
| Units: Pearson's correlation coefficient |                      |  |  |  |
| number (not applicable)                  |                      |  |  |  |
| AUC(0-tau), n=13, 14, 15, 0              | -0.005               |  |  |  |
| Cmax, n=13, 14, 15, 0                    | 0.037                |  |  |  |
| C0avg, n=43, 40, 42, 0                   | -0.011               |  |  |  |

|                       |        |  |  |  |
|-----------------------|--------|--|--|--|
| Ctau, n=13, 14, 15, 0 | -0.055 |  |  |  |
|-----------------------|--------|--|--|--|

## Statistical analyses

No statistical analyses for this end point

### Secondary: Relationship between the indicated safety parameters at Week 96 and the indicated plasma DTG PK parameters

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Relationship between the indicated safety parameters at Week 96 and the indicated plasma DTG PK parameters |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                            |
| Relationships between log-transformed plasma DTG PK parameters (AUC[0-tau], Cmax, C0, C0avg, Ctau, and Cmin) and safety parameters (AE occurrence, maximum AE intensity, alanine aminotransferase [ALT], change from Baseline [CFB] in ALT, total bilirubin, CFB in total bilirubin, creatine kinase, CFB in creatine kinase, triglycerides, CFB in triglycerides, lipase, CFB in lipase, total cholesterol [TC], CFB in TC) was assessed using Pearson's correlation analyses. The Pearson's correlation coefficient is a measure of the correlation between safety parameters and plasma DTG PK parameters and ranges from -1 to 1. A value of 0 indicates no statistical association; a value close to -1 or 1 indicates a higher association. The presence of $\geq 1$ AE was used for AE occurrence. The most severe AE grade/intensity was used for maximum AE intensity. Maximum laboratory values per participant were used for safety parameters. CFB was calculated as the post-Baseline value minus the value at Baseline. |                                                                                                            |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Secondary                                                                                                  |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                            |
| Week 96                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                            |

| End point values                               | Overall DTG          |  |  |  |
|------------------------------------------------|----------------------|--|--|--|
| Subject group type                             | Subject analysis set |  |  |  |
| Number of subjects analysed                    | 142                  |  |  |  |
| Units: Pearson's correlation coefficient       |                      |  |  |  |
| number (not applicable)                        |                      |  |  |  |
| AUC(0-tau) versus AE occurrence, n=45          | 0.114                |  |  |  |
| AUC(0-tau) versus maximum AE intensity, n=45   | 0.171                |  |  |  |
| AUC(0-tau) versus ALT, n=45                    | -0.196               |  |  |  |
| AUC(0-tau) versus CFB in ALT, n=45             | -0.201               |  |  |  |
| AUC(0-tau) versus total bilirubin, n=45        | 0.364                |  |  |  |
| AUC(0-tau) versus CFB in total bilirubin, n=45 | 0.147                |  |  |  |
| AUC(0-tau) versus creatine kinase, n=45        | -0.168               |  |  |  |
| AUC(0-tau) versus CFB in creatine kinase, n=45 | -0.145               |  |  |  |
| AUC(0-tau) vs Triglycerides, n=45              | 0.104                |  |  |  |
| AUC(0-tau) versus CFB in triglycerides, n=45   | 0.216                |  |  |  |
| AUC(0-tau) versus lipase, n=45                 | -0.066               |  |  |  |
| AUC(0-tau) versus CFB in lipase, n=45          | 0.092                |  |  |  |

|                                                  |        |  |  |  |
|--------------------------------------------------|--------|--|--|--|
| AUC(0-tau) versus total cholesterol, n=45        | -0.097 |  |  |  |
| AUC(0-tau) versus CFB in total cholesterol, n=45 | -0.153 |  |  |  |
| Cmax versus AE occurrence, n=45                  | 0.061  |  |  |  |
| Cmax versus maximum AE intensity, n=45           | 0.110  |  |  |  |
| Cmax versus ALT, n=45                            | -0.135 |  |  |  |
| Cmax versus CFB in ALT, n=45                     | -0.135 |  |  |  |
| Cmax versus total bilirubin, n=45                | 0.265  |  |  |  |
| Cmax versus CFB in total bilirubin, n=45         | 0.033  |  |  |  |
| Cmax versus creatine kinase, n=45                | -0.188 |  |  |  |
| Cmax versus CFB in creatine kinase, n=45         | -0.161 |  |  |  |
| Cmax versus triglycerides, n=45                  | 0.134  |  |  |  |
| Cmax versus CFB in triglycerides, n=45           | 0.244  |  |  |  |
| Cmax versus lipase, n=45                         | -0.034 |  |  |  |
| Cmax versus CFB in lipase, n=45                  | 0.115  |  |  |  |
| Cmax versus total cholesterol, n=45              | -0.101 |  |  |  |
| Cmax versus CFB in total cholesterol, n=45       | -0.192 |  |  |  |
| C0 versus AE occurrence, n=133                   | -0.080 |  |  |  |
| C0 versus maximum AE intensity, n=133            | -0.003 |  |  |  |
| C0 versus ALT, n=133                             | -0.196 |  |  |  |
| C0 versus CFB in ALT, n=133                      | -0.237 |  |  |  |
| C0 versus total bilirubin, n=133                 | 0.298  |  |  |  |
| C0 versus CFB in total bilirubin, n=133          | 0.120  |  |  |  |
| C0 versus creatine kinase, n=133                 | -0.094 |  |  |  |
| C0 versus CFB in creatine kinase, n=133          | -0.093 |  |  |  |
| C0 versus triglycerides, n=133                   | -0.058 |  |  |  |
| C0 versus CFB in triglycerides, n=133            | -0.012 |  |  |  |
| C0 versus lipase, n=133                          | -0.187 |  |  |  |
| C0 versus CFB in lipase, n=133                   | -0.137 |  |  |  |
| C0 versus total cholesterol, n=133               | -0.179 |  |  |  |
| C0 versus CFB in total cholesterol, n=133        | -0.125 |  |  |  |
| C0avg versus AE occurrence, n=140                | -0.028 |  |  |  |
| C0avg versus maximum AE intensity, n=140         | 0.036  |  |  |  |
| C0avg versus ALT, n=140                          | -0.166 |  |  |  |
| C0avg versus CFB in ALT, n=140                   | -0.177 |  |  |  |
| C0avg versus total bilirubin, n=140              | 0.319  |  |  |  |
| C0avg versus CFB in total bilirubin, n=140       | 0.109  |  |  |  |
| C0avg versus creatine kinase, n=140              | -0.114 |  |  |  |
| C0avg versus CFB in creatine kinase, n=140       | -0.110 |  |  |  |
| C0avg versus triglycerides, n=140                | 0.057  |  |  |  |
| C0avg versus CFB in triglycerides, n=140         | 0.092  |  |  |  |
| C0avg versus lipase, n=140                       | -0.164 |  |  |  |
| C0avg versus CFB in lipase, n=140                | -0.120 |  |  |  |
| C0avg versus total cholesterol, n=140            | -0.170 |  |  |  |

|                                              |        |  |  |  |
|----------------------------------------------|--------|--|--|--|
| C0avg versus CFB in total cholesterol, n=140 | -0.083 |  |  |  |
| Ctau versus AE occurrence, n=45              | 0.190  |  |  |  |
| Ctau versus maximum AE intensity, n=45       | 0.205  |  |  |  |
| Ctau versus ALT, n=45                        | -0.281 |  |  |  |
| Ctau versus CFB in ALT, n=45                 | -0.285 |  |  |  |
| Ctau versus total bilirubin, n=45            | 0.446  |  |  |  |
| Ctau versus CFB in total bilirubin, n=45     | 0.237  |  |  |  |
| Ctau versus creatine kinase, n=45            | -0.143 |  |  |  |
| Ctau versus CFB in creatine kinase, n=45     | -0.125 |  |  |  |
| Ctau versus triglycerides, n=45              | 0.061  |  |  |  |
| Ctau versus CFB in triglycerides, n=45       | 0.172  |  |  |  |
| Ctau versus lipase, n=45                     | -0.131 |  |  |  |
| Ctau versus CFB in lipase, n=45              | 0.056  |  |  |  |
| Ctau versus total cholesterol, n=45          | -0.039 |  |  |  |
| Ctau versus CFB in total cholesterol, n=45   | -0.108 |  |  |  |
| Cmin versus AE occurrence, n=45              | 0.156  |  |  |  |
| Cmin versus maximum AE intensity, n=45       | 0.193  |  |  |  |
| Cmin versus ALT, n=45                        | -0.236 |  |  |  |
| Cmin versus CFB in ALT, n=45                 | -0.253 |  |  |  |
| Cmin versus total bilirubin, n=45            | 0.430  |  |  |  |
| Cmin versus CFB in total bilirubin, n=45     | 0.171  |  |  |  |
| Cmin versus creatine kinase, n=45            | -0.132 |  |  |  |
| Cmin versus CFB in creatine kinase, n=45     | -0.124 |  |  |  |
| Cmin versus triglycerides, n=45              | -0.042 |  |  |  |
| Cmin versus CFB in triglycerides, n=45       | 0.057  |  |  |  |
| Cmin versus lipase, n=45                     | -0.135 |  |  |  |
| Cmin versus CFB in lipase, n=45              | 0.032  |  |  |  |
| Cmin versus total cholesterol, n=45          | -0.194 |  |  |  |
| Cmin versus CFB in total cholesterol, n=45   | -0.208 |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Relationship between gastrointestinal system organ class AEs of special interest at Week 96 and the indicated plasma DTG PK parameters

|                 |                                                                                                                                        |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Relationship between gastrointestinal system organ class AEs of special interest at Week 96 and the indicated plasma DTG PK parameters |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Logistic regressions were performed to examine the correlation between plasma DTG PK parameters (AUC[0-tau] [area under the time concentration curve over the dosing interval], Cmax [maximal concentration], Ctau [concentration at the end of the dosing interval], and C0avg [average pre-dose concentration]) on log scales and the presence of gastrointestinal system organ class AEs (abdominal pain, diarrhea, nausea, and vomiting) at Week 96. Data are presented as estimates from logistic regression, which is a measure of the association between AEs of special interest and plasma DTG PK parameters. A value of 0 indicates no statistical association; a large absolute value of the estimate

indicates higher association. Because PK was assessed for DTG, no participants in the EFV treatment group were analyzed. Results are presented for participants in any DTG group (overall DTG). Only those participants available at the specified time points were analyzed represented by n=X in the category titles

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 96              |           |

| End point values                       | Overall DTG          |  |  |  |
|----------------------------------------|----------------------|--|--|--|
| Subject group type                     | Subject analysis set |  |  |  |
| Number of subjects analysed            | 142 <sup>[23]</sup>  |  |  |  |
| Units: estimated effect                |                      |  |  |  |
| number (not applicable)                |                      |  |  |  |
| Abdominal pain versus AUC(0-tau), n=45 | -2.49                |  |  |  |
| Abdominal pain versus Cmax, n=45       | -2.98                |  |  |  |
| Abdominal pain versus Ctau, n=45       | -1.72                |  |  |  |
| Abdominal pain versus C0avg, n=140     | -0.41                |  |  |  |
| Diarrhoea versus AUC(0-tau), n=45      | -0.62                |  |  |  |
| Diarrhoea versus Cmax, n=45            | -0.98                |  |  |  |
| Diarrhoea versus Ctau, n=45            | -0.29                |  |  |  |
| Diarrhoea versus C0avg, n=140          | 0.13                 |  |  |  |
| Nausea versus AUC(0-tau), n=45         | -0.31                |  |  |  |
| Nausea versus Cmax, n=45               | -0.72                |  |  |  |
| Nausea versus Ctau, n=45               | 0.03                 |  |  |  |
| Nausea versus C0avg, n=140             | -0.32                |  |  |  |
| Vomiting versus AUC(0-tau), n=45       | -1.29                |  |  |  |
| Vomiting versus Cmax, n=45             | -1.61                |  |  |  |
| Vomiting versus Ctau, n=45             | -1.15                |  |  |  |
| Vomiting versus C0avg, n=140           | -0.89                |  |  |  |

Notes:

[23] - PK/PD Analysis Population.

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Change from Baseline in cluster of differentiation 8+ (CD8+) cell counts at the indicated time points

|                 |                                                                                                       |
|-----------------|-------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline in cluster of differentiation 8+ (CD8+) cell counts at the indicated time points |
|-----------------|-------------------------------------------------------------------------------------------------------|

End point description:

Change from Baseline in CD8+ cell count data are not available; CD8+ data are only listed on a per-participant basis and were not summarized.

|                |                     |
|----------------|---------------------|
| End point type | Other pre-specified |
|----------------|---------------------|

End point timeframe:

Baseline (Day 1), Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 60, Week 72, Week 84, and Week 96

| <b>End point values</b>               | DTG 10 mg QD      | DTG 25 mg QD      | DTG 50 mg QD      | EFV 600 mg QD     |
|---------------------------------------|-------------------|-------------------|-------------------|-------------------|
| Subject group type                    | Reporting group   | Reporting group   | Reporting group   | Reporting group   |
| Number of subjects analysed           | 0 <sup>[24]</sup> | 0 <sup>[25]</sup> | 0 <sup>[26]</sup> | 0 <sup>[27]</sup> |
| Units: Cells per cubic millimeter     |                   |                   |                   |                   |
| median (inter-quartile range (Q1-Q3)) |                   |                   |                   |                   |
| Cells per cubic millimeter            | ( to )            | ( to )            | ( to )            | ( to )            |

Notes:

[24] - ITT-E Population.

[25] - ITT-E Population.

[26] - ITT-E Population.

[27] - ITT-E Population.

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs) and non-serious AEs were collected in the time period from Baseline up to end of study.

Adverse event reporting additional description:

SAEs and AEs were collected in members of Safety Population, comprised of all participants who received at least one dose of study medication.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 20.0 |
|--------------------|------|

### Reporting groups

|                       |             |
|-----------------------|-------------|
| Reporting group title | DTG 10mg QD |
|-----------------------|-------------|

Reporting group description:

Participants received DTG 10 mg, DTG matching placebo, and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.

|                       |             |
|-----------------------|-------------|
| Reporting group title | DTG 25mg QD |
|-----------------------|-------------|

Reporting group description:

Participants received DTG 25 mg, DTG matching placebo, and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.

|                       |             |
|-----------------------|-------------|
| Reporting group title | DTG 50mg QD |
|-----------------------|-------------|

Reporting group description:

Participants received DTG 50 mg and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.

|                       |           |
|-----------------------|-----------|
| Reporting group title | EFV 600mg |
|-----------------------|-----------|

Reporting group description:

Participants received Efavirenz (EFV) 600 mg and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally QD for 96 weeks.

|                       |                         |
|-----------------------|-------------------------|
| Reporting group title | Open-label DTG 50 mg QD |
|-----------------------|-------------------------|

Reporting group description:

All DTG participants were switched to or continued DTG 50 mg with either ABC/3TC orally at 600 mg/300 mg (1 tablet) or TDF/FTC orally QD during the Open label phase

| Serious adverse events                                              | DTG 10mg QD     | DTG 25mg QD    | DTG 50mg QD     |
|---------------------------------------------------------------------|-----------------|----------------|-----------------|
| Total subjects affected by serious adverse events                   |                 |                |                 |
| subjects affected / exposed                                         | 6 / 53 (11.32%) | 4 / 51 (7.84%) | 7 / 51 (13.73%) |
| number of deaths (all causes)                                       | 2               | 0              | 0               |
| number of deaths resulting from adverse events                      |                 |                |                 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                 |                |                 |
| Burkitt's lymphoma                                                  |                 |                |                 |
| subjects affected / exposed                                         | 0 / 53 (0.00%)  | 0 / 51 (0.00%) | 1 / 51 (1.96%)  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0          | 0 / 0           |

|                                                      |                |                |                |
|------------------------------------------------------|----------------|----------------|----------------|
| Vascular disorders                                   |                |                |                |
| Phlebitis                                            |                |                |                |
| subjects affected / exposed                          | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| General disorders and administration site conditions |                |                |                |
| Pyrexia                                              |                |                |                |
| subjects affected / exposed                          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Systemic inflammatory response syndrome              |                |                |                |
| subjects affected / exposed                          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Reproductive system and breast disorders             |                |                |                |
| Dysmenorrhoea                                        |                |                |                |
| subjects affected / exposed                          | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Psychiatric disorders                                |                |                |                |
| Anxiety                                              |                |                |                |
| subjects affected / exposed                          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Depression                                           |                |                |                |
| subjects affected / exposed                          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Suicide attempt                                      |                |                |                |
| subjects affected / exposed                          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Product issues                                       |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Device malfunction                              |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 2          | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural complications  |                |                |                |
| Wrist fracture                                  |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Foot fracture                                   |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 2          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Humerus fracture                                |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Injury                                          |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Joint dislocation                               |                |                |                |
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Multiple injuries                               |                |                |                |
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 1          | 0 / 0          | 0 / 0          |
| Road traffic accident                           |                |                |                |
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 1          | 0 / 0          | 0 / 0          |

|                                                            |                |                |                |
|------------------------------------------------------------|----------------|----------------|----------------|
| Spinal compression fracture<br>subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                                          |                |                |                |
| Acute myocardial infarction<br>subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 0          | 1 / 1          |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0          |
| Myocardial infarction<br>subjects affected / exposed       | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                                   |                |                |                |
| Headache<br>subjects affected / exposed                    | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0          |
| Hydrocephalus<br>subjects affected / exposed               | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0          |
| Seizure<br>subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                                 |                |                |                |
| Constipation<br>subjects affected / exposed                | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to<br>treatment / all         | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0          |
| Flatulence                                                 |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Inguinal hernia                                 |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Mallory-Weiss syndrome                          |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nausea                                          |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Upper gastrointestinal haemorrhage              |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Hepatobiliary disorders                         |                |                |                |
| Cholelithiasis                                  |                |                |                |
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Back pain                                       |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Osteoarthritis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Tendonitis                                      |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Abscess                                         |                |                |                |
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Bronchitis                                      |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Diverticulitis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Epididymitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastroenteritis                                 |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Herpes zoster                                   |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Meningitis                                      |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Neurosyphilis                                   |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumococcal sepsis                             |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia pneumococcal                          |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Primary syphilis                                |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pyelonephritis acute                            |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Lipomatosis                                     |                |                |                |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Obesity                                         |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| <b>Serious adverse events</b>                                       | EFV 600mg       | Open-label DTG 50 mg QD |  |
|---------------------------------------------------------------------|-----------------|-------------------------|--|
| Total subjects affected by serious adverse events                   |                 |                         |  |
| subjects affected / exposed                                         | 7 / 50 (14.00%) | 16 / 138 (11.59%)       |  |
| number of deaths (all causes)                                       | 0               | 2                       |  |
| number of deaths resulting from adverse events                      |                 |                         |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                 |                         |  |
| Burkitt's lymphoma                                                  |                 |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)  | 0 / 138 (0.00%)         |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0                   |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0                   |  |
| Vascular disorders                                                  |                 |                         |  |
| Phlebitis                                                           |                 |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)  | 0 / 138 (0.00%)         |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0                   |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0                   |  |
| General disorders and administration site conditions                |                 |                         |  |
| Pyrexia                                                             |                 |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)  | 0 / 138 (0.00%)         |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0                   |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0                   |  |
| Systemic inflammatory response syndrome                             |                 |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)  | 1 / 138 (0.72%)         |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 1                   |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0                   |  |
| Reproductive system and breast disorders                            |                 |                         |  |
| Dysmenorrhoea                                                       |                 |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)  | 0 / 138 (0.00%)         |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0                   |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0                   |  |
| Psychiatric disorders                                               |                 |                         |  |

|                                                 |                |                 |  |
|-------------------------------------------------|----------------|-----------------|--|
| Anxiety                                         |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Depression                                      |                |                 |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Suicide attempt                                 |                |                 |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Product issues                                  |                |                 |  |
| Device malfunction                              |                |                 |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 2           |  |
| Injury, poisoning and procedural complications  |                |                 |  |
| Wrist fracture                                  |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Foot fracture                                   |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Humerus fracture                                |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Injury                                          |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1           |  |

|                                                 |                |                 |  |
|-------------------------------------------------|----------------|-----------------|--|
| Joint dislocation                               |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Multiple injuries                               |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Road traffic accident                           |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Spinal compression fracture                     |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Cardiac disorders                               |                |                 |  |
| Acute myocardial infarction                     |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Myocardial infarction                           |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1           |  |
| Nervous system disorders                        |                |                 |  |
| Headache                                        |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Hydrocephalus                                   |                |                 |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |

|                                                 |                |                 |  |
|-------------------------------------------------|----------------|-----------------|--|
| Seizure                                         |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Gastrointestinal disorders                      |                |                 |  |
| Constipation                                    |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Flatulence                                      |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Inguinal hernia                                 |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Mallory-Weiss syndrome                          |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Nausea                                          |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Upper gastrointestinal haemorrhage              |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Hepatobiliary disorders                         |                |                 |  |
| Cholelithiasis                                  |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |

|                                                 |                |                 |  |
|-------------------------------------------------|----------------|-----------------|--|
| Musculoskeletal and connective tissue disorders |                |                 |  |
| Back pain                                       |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 3           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Osteoarthritis                                  |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 3           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Tendonitis                                      |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Infections and infestations                     |                |                 |  |
| Pneumonia                                       |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Abscess                                         |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Appendicitis                                    |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Bronchitis                                      |                |                 |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Diverticulitis                                  |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |

|                                                 |                |                 |  |
|-------------------------------------------------|----------------|-----------------|--|
| Epididymitis                                    |                |                 |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Gastroenteritis                                 |                |                 |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Herpes zoster                                   |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Meningitis                                      |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Neurosyphilis                                   |                |                 |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Pneumococcal sepsis                             |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Pneumonia pneumococcal                          |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Primary syphilis                                |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| Pyelonephritis acute                            |                |                 |  |

|                                                 |                |                 |  |
|-------------------------------------------------|----------------|-----------------|--|
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| <b>Metabolism and nutrition disorders</b>       |                |                 |  |
| <b>Lipomatosis</b>                              |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |
| <b>Obesity</b>                                  |                |                 |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           |  |

Frequency threshold for reporting non-serious adverse events: 0 %

| <b>Non-serious adverse events</b>                                          | DTG 10mg QD      | DTG 25mg QD      | DTG 50mg QD      |
|----------------------------------------------------------------------------|------------------|------------------|------------------|
| <b>Total subjects affected by non-serious adverse events</b>               |                  |                  |                  |
| subjects affected / exposed                                                | 49 / 53 (92.45%) | 46 / 51 (90.20%) | 45 / 51 (88.24%) |
| <b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b> |                  |                  |                  |
| <b>Anogenital warts</b>                                                    |                  |                  |                  |
| subjects affected / exposed                                                | 2 / 53 (3.77%)   | 0 / 51 (0.00%)   | 1 / 51 (1.96%)   |
| occurrences (all)                                                          | 4                | 0                | 1                |
| <b>Melanocytic naevus</b>                                                  |                  |                  |                  |
| subjects affected / exposed                                                | 1 / 53 (1.89%)   | 0 / 51 (0.00%)   | 0 / 51 (0.00%)   |
| occurrences (all)                                                          | 1                | 0                | 0                |
| <b>Infected naevus</b>                                                     |                  |                  |                  |
| subjects affected / exposed                                                | 1 / 53 (1.89%)   | 0 / 51 (0.00%)   | 0 / 51 (0.00%)   |
| occurrences (all)                                                          | 1                | 0                | 0                |
| <b>Papilloma</b>                                                           |                  |                  |                  |
| subjects affected / exposed                                                | 0 / 53 (0.00%)   | 0 / 51 (0.00%)   | 1 / 51 (1.96%)   |
| occurrences (all)                                                          | 0                | 0                | 1                |
| <b>Prostatic adenoma</b>                                                   |                  |                  |                  |
| subjects affected / exposed                                                | 0 / 53 (0.00%)   | 0 / 51 (0.00%)   | 0 / 51 (0.00%)   |
| occurrences (all)                                                          | 0                | 0                | 0                |
| <b>Skin papilloma</b>                                                      |                  |                  |                  |

|                                                         |                     |                     |                     |
|---------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)        | 0 / 53 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 | 0 / 51 (0.00%)<br>0 |
| Vascular disorders                                      |                     |                     |                     |
| Hypertension                                            |                     |                     |                     |
| subjects affected / exposed                             | 0 / 53 (0.00%)      | 2 / 51 (3.92%)      | 0 / 51 (0.00%)      |
| occurrences (all)                                       | 0                   | 2                   | 0                   |
| Aortic arteriosclerosis                                 |                     |                     |                     |
| subjects affected / exposed                             | 0 / 53 (0.00%)      | 0 / 51 (0.00%)      | 1 / 51 (1.96%)      |
| occurrences (all)                                       | 0                   | 0                   | 1                   |
| Arterial fibrosis                                       |                     |                     |                     |
| subjects affected / exposed                             | 0 / 53 (0.00%)      | 1 / 51 (1.96%)      | 0 / 51 (0.00%)      |
| occurrences (all)                                       | 0                   | 1                   | 0                   |
| Hot flush                                               |                     |                     |                     |
| subjects affected / exposed                             | 0 / 53 (0.00%)      | 0 / 51 (0.00%)      | 0 / 51 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Peripheral coldness                                     |                     |                     |                     |
| subjects affected / exposed                             | 0 / 53 (0.00%)      | 0 / 51 (0.00%)      | 0 / 51 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Peripheral venous disease                               |                     |                     |                     |
| subjects affected / exposed                             | 0 / 53 (0.00%)      | 0 / 51 (0.00%)      | 0 / 51 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Phlebitis                                               |                     |                     |                     |
| subjects affected / exposed                             | 0 / 53 (0.00%)      | 0 / 51 (0.00%)      | 0 / 51 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| General disorders and administration<br>site conditions |                     |                     |                     |
| Pyrexia                                                 |                     |                     |                     |
| subjects affected / exposed                             | 5 / 53 (9.43%)      | 4 / 51 (7.84%)      | 1 / 51 (1.96%)      |
| occurrences (all)                                       | 5                   | 4                   | 1                   |
| Fatigue                                                 |                     |                     |                     |
| subjects affected / exposed                             | 2 / 53 (3.77%)      | 4 / 51 (7.84%)      | 2 / 51 (3.92%)      |
| occurrences (all)                                       | 2                   | 7                   | 2                   |
| Asthenia                                                |                     |                     |                     |
| subjects affected / exposed                             | 4 / 53 (7.55%)      | 2 / 51 (3.92%)      | 1 / 51 (1.96%)      |
| occurrences (all)                                       | 4                   | 3                   | 1                   |
| Influenza like illness                                  |                     |                     |                     |

|                                       |                |                |                |
|---------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed           | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 2 / 51 (3.92%) |
| occurrences (all)                     | 1              | 0              | 2              |
| Chest pain                            |                |                |                |
| subjects affected / exposed           | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                     | 1              | 1              | 0              |
| Malaise                               |                |                |                |
| subjects affected / exposed           | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                     | 0              | 0              | 1              |
| Oedema peripheral                     |                |                |                |
| subjects affected / exposed           | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                     | 0              | 0              | 0              |
| Pain                                  |                |                |                |
| subjects affected / exposed           | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                     | 0              | 0              | 0              |
| Adverse drug reaction                 |                |                |                |
| subjects affected / exposed           | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                     | 0              | 1              | 0              |
| Chest discomfort                      |                |                |                |
| subjects affected / exposed           | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                     | 0              | 0              | 1              |
| Drug intolerance                      |                |                |                |
| subjects affected / exposed           | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                     | 0              | 0              | 0              |
| Feeling drunk                         |                |                |                |
| subjects affected / exposed           | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                     | 0              | 0              | 0              |
| Feeling hot                           |                |                |                |
| subjects affected / exposed           | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                     | 0              | 0              | 0              |
| General physical health deterioration |                |                |                |
| subjects affected / exposed           | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                     | 0              | 0              | 0              |
| Injection site pain                   |                |                |                |
| subjects affected / exposed           | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                     | 0              | 0              | 0              |
| Nodule                                |                |                |                |

|                                                                                |                     |                     |                     |
|--------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                               | 0 / 53 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 | 0 / 51 (0.00%)<br>0 |
| Oedema<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Immune system disorders                                                        |                     |                     |                     |
| Seasonal allergy<br>subjects affected / exposed<br>occurrences (all)           | 1 / 53 (1.89%)<br>1 | 2 / 51 (3.92%)<br>2 | 1 / 51 (1.96%)<br>1 |
| Allergy to arthropod sting<br>subjects affected / exposed<br>occurrences (all) | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 |
| Drug hypersensitivity<br>subjects affected / exposed<br>occurrences (all)      | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Food allergy<br>subjects affected / exposed<br>occurrences (all)               | 1 / 53 (1.89%)<br>1 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Hypersensitivity<br>subjects affected / exposed<br>occurrences (all)           | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Multiple allergies<br>subjects affected / exposed<br>occurrences (all)         | 1 / 53 (1.89%)<br>2 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Reproductive system and breast disorders                                       |                     |                     |                     |
| Erectile dysfunction<br>subjects affected / exposed<br>occurrences (all)       | 1 / 53 (1.89%)<br>1 | 0 / 51 (0.00%)<br>0 | 2 / 51 (3.92%)<br>2 |
| Genital lesion<br>subjects affected / exposed<br>occurrences (all)             | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Ovarian cyst<br>subjects affected / exposed<br>occurrences (all)               | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Prostatitis                                                                    |                     |                     |                     |

|                                                 |                |                |                 |
|-------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 1 / 51 (1.96%)  |
| occurrences (all)                               | 1              | 0              | 1               |
| Breast discomfort                               |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Breast mass                                     |                |                |                 |
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%)  |
| occurrences (all)                               | 1              | 0              | 0               |
| Cervical dysplasia                              |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Gynaecomastia                                   |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Penile discharge                                |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%)  |
| occurrences (all)                               | 0              | 1              | 0               |
| Peyronie's disease                              |                |                |                 |
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%)  |
| occurrences (all)                               | 1              | 0              | 0               |
| Respiratory, thoracic and mediastinal disorders |                |                |                 |
| Cough                                           |                |                |                 |
| subjects affected / exposed                     | 5 / 53 (9.43%) | 4 / 51 (7.84%) | 6 / 51 (11.76%) |
| occurrences (all)                               | 5              | 4              | 8               |
| Oropharyngeal pain                              |                |                |                 |
| subjects affected / exposed                     | 3 / 53 (5.66%) | 0 / 51 (0.00%) | 3 / 51 (5.88%)  |
| occurrences (all)                               | 3              | 0              | 3               |
| Asthma                                          |                |                |                 |
| subjects affected / exposed                     | 1 / 53 (1.89%) | 2 / 51 (3.92%) | 1 / 51 (1.96%)  |
| occurrences (all)                               | 1              | 3              | 1               |
| Sinus congestion                                |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 2 / 51 (3.92%)  |
| occurrences (all)                               | 0              | 1              | 2               |
| Dyspnoea                                        |                |                |                 |

|                                    |                |                |                |
|------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed        | 0 / 53 (0.00%) | 2 / 51 (3.92%) | 1 / 51 (1.96%) |
| occurrences (all)                  | 0              | 2              | 1              |
| Rhinitis allergic                  |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)                  | 0              | 2              | 1              |
| Lung disorder                      |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 0              | 1              | 0              |
| Respiratory disorder               |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)                  | 0              | 1              | 1              |
| Rhinorrhoea                        |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 2 / 51 (3.92%) |
| occurrences (all)                  | 0              | 0              | 2              |
| Asthmatic crisis                   |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 0              | 1              | 0              |
| Bronchitis chronic                 |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 0              | 1              | 0              |
| Bronchopneumopathy                 |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 0              | 0              | 0              |
| Dysphonia                          |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                  | 0              | 0              | 1              |
| Hyperventilation                   |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 0              | 0              | 0              |
| Lower respiratory tract congestion |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                  | 0              | 0              | 1              |
| Nasal congestion                   |                |                |                |
| subjects affected / exposed        | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 1              | 0              | 0              |
| Pharyngeal disorder                |                |                |                |

|                                    |                |                 |                 |
|------------------------------------|----------------|-----------------|-----------------|
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%)  | 1 / 51 (1.96%)  |
| occurrences (all)                  | 0              | 0               | 1               |
| Respiratory tract congestion       |                |                 |                 |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%)  | 1 / 51 (1.96%)  |
| occurrences (all)                  | 0              | 0               | 1               |
| Sleep apnoea syndrome              |                |                 |                 |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0               |
| Snoring                            |                |                 |                 |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0               |
| Upper respiratory tract congestion |                |                 |                 |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0               |
| Upper-airway cough syndrome        |                |                 |                 |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0               |
| Psychiatric disorders              |                |                 |                 |
| Insomnia                           |                |                 |                 |
| subjects affected / exposed        | 0 / 53 (0.00%) | 7 / 51 (13.73%) | 6 / 51 (11.76%) |
| occurrences (all)                  | 0              | 7               | 6               |
| Depression                         |                |                 |                 |
| subjects affected / exposed        | 3 / 53 (5.66%) | 6 / 51 (11.76%) | 2 / 51 (3.92%)  |
| occurrences (all)                  | 3              | 6               | 3               |
| Anxiety                            |                |                 |                 |
| subjects affected / exposed        | 1 / 53 (1.89%) | 2 / 51 (3.92%)  | 2 / 51 (3.92%)  |
| occurrences (all)                  | 2              | 2               | 2               |
| Abnormal dreams                    |                |                 |                 |
| subjects affected / exposed        | 1 / 53 (1.89%) | 2 / 51 (3.92%)  | 0 / 51 (0.00%)  |
| occurrences (all)                  | 1              | 2               | 0               |
| Nightmare                          |                |                 |                 |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)                  | 0              | 0               | 0               |
| Stress                             |                |                 |                 |
| subjects affected / exposed        | 0 / 53 (0.00%) | 1 / 51 (1.96%)  | 2 / 51 (3.92%)  |
| occurrences (all)                  | 0              | 1               | 2               |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| Acute stress disorder       |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Loss of libido              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Sleep disorder              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Affect lability             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Anxiety disorder            |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Bulimia nervosa             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Disorientation              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Hallucination               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Libido increased            |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Listless                    |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Mental disorder             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Panic attack                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |

|                                                                                            |                     |                     |                     |
|--------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Post-traumatic stress disorder<br>subjects affected / exposed<br>occurrences (all)         | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Substance use disorder<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Investigations                                                                             |                     |                     |                     |
| Blood creatine phosphokinase increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 53 (0.00%)<br>0 | 3 / 51 (5.88%)<br>3 | 0 / 51 (0.00%)<br>0 |
| Blood cholesterol increased<br>subjects affected / exposed<br>occurrences (all)            | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 |
| Alanine aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)     | 0 / 53 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 | 1 / 51 (1.96%)<br>1 |
| Blood glucose increased<br>subjects affected / exposed<br>occurrences (all)                | 0 / 53 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 | 0 / 51 (0.00%)<br>0 |
| Lipase increased<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Amylase increased<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Anal pap smear abnormal<br>subjects affected / exposed<br>occurrences (all)                | 0 / 53 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 | 0 / 51 (0.00%)<br>0 |
| Bacterial test positive<br>subjects affected / exposed<br>occurrences (all)                | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Blood creatinine increased<br>subjects affected / exposed<br>occurrences (all)             | 0 / 53 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 | 0 / 51 (0.00%)<br>0 |
| Cardiac murmur                                                                             |                     |                     |                     |

|                                                |                |                |                |
|------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Electrocardiogram repolarisation abnormality   |                |                |                |
| subjects affected / exposed                    | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                              | 0              | 1              | 0              |
| Liver function test increased                  |                |                |                |
| subjects affected / exposed                    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Neutrophil count decreased                     |                |                |                |
| subjects affected / exposed                    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                              | 0              | 0              | 1              |
| Transaminases increased                        |                |                |                |
| subjects affected / exposed                    | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                              | 0              | 1              | 0              |
| Urinary sediment present                       |                |                |                |
| subjects affected / exposed                    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Weight decreased                               |                |                |                |
| subjects affected / exposed                    | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                              | 0              | 1              | 0              |
| Weight increased                               |                |                |                |
| subjects affected / exposed                    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Injury, poisoning and procedural complications |                |                |                |
| Ligament sprain                                |                |                |                |
| subjects affected / exposed                    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Concussion                                     |                |                |                |
| subjects affected / exposed                    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Contusion                                      |                |                |                |
| subjects affected / exposed                    | 2 / 53 (3.77%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                              | 2              | 0              | 0              |
| Laceration                                     |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 53 (0.00%) | 2 / 51 (3.92%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 2              | 0              |
| Limb injury                 |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Muscle strain               |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Procedural pain             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Anal injury                 |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Cervical vertebral fracture |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Clavicle fracture           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Epicondylitis               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Face injury                 |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Fall                        |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Foot fracture               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Joint dislocation           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Rib fracture                |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Scrotal haematoma           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Stress fracture             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Tendon rupture              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Vaccination complication    |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Wrist fracture              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Cardiac disorders           |                |                |                |
| Sinus tachycardia           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Tachycardia                 |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Aortic valve incompetence   |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Arrhythmia                  |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Bradycardia                 |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Cardiomegaly                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |

|                             |                 |                 |                 |
|-----------------------------|-----------------|-----------------|-----------------|
| Palpitations                |                 |                 |                 |
| subjects affected / exposed | 0 / 53 (0.00%)  | 1 / 51 (1.96%)  | 0 / 51 (0.00%)  |
| occurrences (all)           | 0               | 1               | 0               |
| Nervous system disorders    |                 |                 |                 |
| Headache                    |                 |                 |                 |
| subjects affected / exposed | 7 / 53 (13.21%) | 6 / 51 (11.76%) | 8 / 51 (15.69%) |
| occurrences (all)           | 9               | 10              | 12              |
| Dizziness                   |                 |                 |                 |
| subjects affected / exposed | 2 / 53 (3.77%)  | 3 / 51 (5.88%)  | 3 / 51 (5.88%)  |
| occurrences (all)           | 2               | 4               | 3               |
| Paraesthesia                |                 |                 |                 |
| subjects affected / exposed | 3 / 53 (5.66%)  | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)           | 3               | 0               | 0               |
| Somnolence                  |                 |                 |                 |
| subjects affected / exposed | 2 / 53 (3.77%)  | 1 / 51 (1.96%)  | 1 / 51 (1.96%)  |
| occurrences (all)           | 2               | 1               | 1               |
| Dysgeusia                   |                 |                 |                 |
| subjects affected / exposed | 2 / 53 (3.77%)  | 1 / 51 (1.96%)  | 0 / 51 (0.00%)  |
| occurrences (all)           | 2               | 1               | 0               |
| Memory impairment           |                 |                 |                 |
| subjects affected / exposed | 1 / 53 (1.89%)  | 0 / 51 (0.00%)  | 1 / 51 (1.96%)  |
| occurrences (all)           | 1               | 0               | 2               |
| Sciatica                    |                 |                 |                 |
| subjects affected / exposed | 0 / 53 (0.00%)  | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)           | 0               | 0               | 0               |
| Hypoaesthesia               |                 |                 |                 |
| subjects affected / exposed | 1 / 53 (1.89%)  | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Poor quality sleep          |                 |                 |                 |
| subjects affected / exposed | 1 / 53 (1.89%)  | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Restless legs syndrome      |                 |                 |                 |
| subjects affected / exposed | 0 / 53 (0.00%)  | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)           | 0               | 0               | 0               |
| Syncope                     |                 |                 |                 |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Ageusia                     |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Anosmia                     |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Cervical radiculopathy      |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Cluster headache            |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Cognitive disorder          |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Hyperaesthesia              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Hypertonia                  |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Migraine                    |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Neuropathy peripheral       |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Post herpetic neuralgia     |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Presyncope                  |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Sinus headache              |                |                |                |

|                                      |                |                |                |
|--------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                    | 0              | 0              | 1              |
| Tongue biting                        |                |                |                |
| subjects affected / exposed          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                    | 0              | 0              | 1              |
| Tremor                               |                |                |                |
| subjects affected / exposed          | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                    | 1              | 0              | 0              |
| Trigeminal neuralgia                 |                |                |                |
| subjects affected / exposed          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                    | 0              | 0              | 0              |
| Visual field defect                  |                |                |                |
| subjects affected / exposed          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                    | 0              | 0              | 0              |
| Blood and lymphatic system disorders |                |                |                |
| Lymphadenopathy                      |                |                |                |
| subjects affected / exposed          | 2 / 53 (3.77%) | 3 / 51 (5.88%) | 0 / 51 (0.00%) |
| occurrences (all)                    | 2              | 3              | 0              |
| Neutropenia                          |                |                |                |
| subjects affected / exposed          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                    | 0              | 0              | 1              |
| Iron deficiency anaemia              |                |                |                |
| subjects affected / exposed          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                    | 0              | 0              | 1              |
| Lymphadenitis                        |                |                |                |
| subjects affected / exposed          | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                    | 0              | 0              | 1              |
| Ear and labyrinth disorders          |                |                |                |
| Vertigo                              |                |                |                |
| subjects affected / exposed          | 2 / 53 (3.77%) | 1 / 51 (1.96%) | 2 / 51 (3.92%) |
| occurrences (all)                    | 2              | 1              | 2              |
| Tinnitus                             |                |                |                |
| subjects affected / exposed          | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                    | 1              | 0              | 0              |
| Ear pain                             |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 53 (0.00%) | 2 / 51 (3.92%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 2              | 0              |
| Hypoacusis                  |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Cerumen impaction           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Ear congestion              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Ear pruritus                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Presbycusis                 |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Eye disorders               |                |                |                |
| Astigmatism                 |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Chalazion                   |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Dark circles under eyes     |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Myopia                      |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Vision blurred              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Visual acuity reduced       |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |

|                                                                                      |                        |                       |                      |
|--------------------------------------------------------------------------------------|------------------------|-----------------------|----------------------|
| Vitreous floaters<br>subjects affected / exposed<br>occurrences (all)                | 1 / 53 (1.89%)<br>1    | 0 / 51 (0.00%)<br>0   | 0 / 51 (0.00%)<br>0  |
| Gastrointestinal disorders                                                           |                        |                       |                      |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)                        | 6 / 53 (11.32%)<br>6   | 9 / 51 (17.65%)<br>10 | 7 / 51 (13.73%)<br>8 |
| Nausea<br>subjects affected / exposed<br>occurrences (all)                           | 10 / 53 (18.87%)<br>10 | 8 / 51 (15.69%)<br>9  | 6 / 51 (11.76%)<br>6 |
| Haemorrhoids<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 53 (0.00%)<br>0    | 0 / 51 (0.00%)<br>0   | 2 / 51 (3.92%)<br>2  |
| Abdominal pain<br>subjects affected / exposed<br>occurrences (all)                   | 3 / 53 (5.66%)<br>3    | 1 / 51 (1.96%)<br>1   | 2 / 51 (3.92%)<br>2  |
| Dyspepsia<br>subjects affected / exposed<br>occurrences (all)                        | 1 / 53 (1.89%)<br>1    | 2 / 51 (3.92%)<br>3   | 2 / 51 (3.92%)<br>2  |
| Abdominal pain upper<br>subjects affected / exposed<br>occurrences (all)             | 4 / 53 (7.55%)<br>5    | 3 / 51 (5.88%)<br>3   | 1 / 51 (1.96%)<br>1  |
| Gastrooesophageal reflux disease<br>subjects affected / exposed<br>occurrences (all) | 0 / 53 (0.00%)<br>0    | 1 / 51 (1.96%)<br>1   | 0 / 51 (0.00%)<br>0  |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)                         | 3 / 53 (5.66%)<br>3    | 3 / 51 (5.88%)<br>3   | 0 / 51 (0.00%)<br>0  |
| Toothache<br>subjects affected / exposed<br>occurrences (all)                        | 2 / 53 (3.77%)<br>2    | 2 / 51 (3.92%)<br>2   | 1 / 51 (1.96%)<br>2  |
| Gastritis<br>subjects affected / exposed<br>occurrences (all)                        | 1 / 53 (1.89%)<br>1    | 1 / 51 (1.96%)<br>1   | 0 / 51 (0.00%)<br>0  |
| Abdominal discomfort                                                                 |                        |                       |                      |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 2 / 53 (3.77%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)           | 2              | 1              | 1              |
| Constipation                |                |                |                |
| subjects affected / exposed | 2 / 53 (3.77%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 3              | 1              | 0              |
| Proctitis                   |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Faeces soft                 |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 1              | 0              | 1              |
| Haematochezia               |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Anal fissure                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Anal fistula                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Anogenital dysplasia        |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Aphthous ulcer              |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 4              | 0              | 0              |
| Epigastric discomfort       |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Flatulence                  |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 3              | 0              |
| Inguinal hernia             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Rectal haemorrhage          |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Abdominal distension        |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Abdominal pain lower        |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Anal pruritus               |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Anal skin tags              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Anal sphincter hypertonia   |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Anal ulcer                  |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Anorectal disorder          |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Anorectal ulcer             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Change of bowel habit       |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Chronic gastritis           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Dental caries               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Enteritis                   |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Enterocolitis               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Food poisoning              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Gastrointestinal disorder   |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Hiatus hernia               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Hypoaesthesia oral          |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Intestinal polyp            |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Leukoplakia oral            |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Odynophagia                 |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Pancreatic atrophy          |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Perianal erythema           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Rectal polyp                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Stomatitis                  |                |                |                |

|                                        |                |                |                |
|----------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed            | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                      | 0              | 1              | 0              |
| Tongue discolouration                  |                |                |                |
| subjects affected / exposed            | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                      | 0              | 0              | 1              |
| Tongue disorder                        |                |                |                |
| subjects affected / exposed            | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Umbilical hernia                       |                |                |                |
| subjects affected / exposed            | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Hepatobiliary disorders                |                |                |                |
| Hypertransaminasaemia                  |                |                |                |
| subjects affected / exposed            | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                      | 0              | 0              | 1              |
| Hepatic steatosis                      |                |                |                |
| subjects affected / exposed            | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Cholestasis                            |                |                |                |
| subjects affected / exposed            | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Skin and subcutaneous tissue disorders |                |                |                |
| Rash                                   |                |                |                |
| subjects affected / exposed            | 5 / 53 (9.43%) | 3 / 51 (5.88%) | 2 / 51 (3.92%) |
| occurrences (all)                      | 6              | 3              | 2              |
| Pruritus                               |                |                |                |
| subjects affected / exposed            | 2 / 53 (3.77%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                      | 3              | 0              | 1              |
| Dermatitis                             |                |                |                |
| subjects affected / exposed            | 0 / 53 (0.00%) | 3 / 51 (5.88%) | 1 / 51 (1.96%) |
| occurrences (all)                      | 0              | 3              | 1              |
| Alopecia                               |                |                |                |
| subjects affected / exposed            | 2 / 53 (3.77%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                      | 2              | 0              | 1              |
| Eczema                                 |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)           | 1              | 1              | 1              |
| Night sweats                |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 2 / 51 (3.92%) |
| occurrences (all)           | 1              | 1              | 2              |
| Urticaria                   |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Erythema                    |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 1              | 2              |
| Hyperhidrosis               |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Photosensitivity reaction   |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 2 / 51 (3.92%) |
| occurrences (all)           | 0              | 0              | 2              |
| Dry skin                    |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Hyperkeratosis              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Prurigo                     |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Seborrhoeic dermatitis      |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 2              | 0              | 0              |
| Skin hyperpigmentation      |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Actinic keratosis           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Blister                     |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Dermal cyst                 |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Hand dermatitis             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Intertrigo                  |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Lipoatrophy                 |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Miliaria                    |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Palmar erythema             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Pigmentation disorder       |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Pruritus generalised        |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Psoriasis                   |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Rash macular                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Rash maculo-papular         |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Rash papular                |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Rash pruritic               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Skin erosion                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Skin lesion                 |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Solar dermatitis            |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Toxic skin eruption         |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Renal and urinary disorders |                |                |                |
| Dysuria                     |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Proteinuria                 |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 2 / 51 (3.92%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 2              | 1              |
| Nephrolithiasis             |                |                |                |
| subjects affected / exposed | 2 / 53 (3.77%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 2              | 1              | 0              |
| Haematuria                  |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Pollakiuria                 |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Leukocyturia                |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 1              | 0              | 1              |

|                                                                             |                     |                     |                     |
|-----------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Acute kidney injury<br>subjects affected / exposed<br>occurrences (all)     | 0 / 53 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 | 0 / 51 (0.00%)<br>0 |
| Chronic kidney disease<br>subjects affected / exposed<br>occurrences (all)  | 0 / 53 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 | 0 / 51 (0.00%)<br>0 |
| Micturition urgency<br>subjects affected / exposed<br>occurrences (all)     | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Urethral discharge<br>subjects affected / exposed<br>occurrences (all)      | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Urethritis noninfective<br>subjects affected / exposed<br>occurrences (all) | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 |
| Urinary hesitation<br>subjects affected / exposed<br>occurrences (all)      | 0 / 53 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Endocrine disorders                                                         |                     |                     |                     |
| Hypogonadism<br>subjects affected / exposed<br>occurrences (all)            | 2 / 53 (3.77%)<br>2 | 0 / 51 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 |
| Hypothyroidism<br>subjects affected / exposed<br>occurrences (all)          | 1 / 53 (1.89%)<br>1 | 0 / 51 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 |
| Goitre<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 53 (0.00%)<br>0 | 1 / 51 (1.96%)<br>1 | 0 / 51 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders                             |                     |                     |                     |
| Back pain<br>subjects affected / exposed<br>occurrences (all)               | 3 / 53 (5.66%)<br>4 | 2 / 51 (3.92%)<br>2 | 2 / 51 (3.92%)<br>2 |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)              | 1 / 53 (1.89%)<br>1 | 3 / 51 (5.88%)<br>3 | 2 / 51 (3.92%)<br>2 |
| Musculoskeletal pain                                                        |                     |                     |                     |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 53 (1.89%) | 2 / 51 (3.92%) | 3 / 51 (5.88%) |
| occurrences (all)           | 1              | 2              | 3              |
| Myalgia                     |                |                |                |
| subjects affected / exposed | 2 / 53 (3.77%) | 0 / 51 (0.00%) | 2 / 51 (3.92%) |
| occurrences (all)           | 2              | 0              | 2              |
| Muscle spasms               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 4 / 51 (7.84%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 5              | 0              |
| Exostosis                   |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 2 / 51 (3.92%) |
| occurrences (all)           | 1              | 0              | 2              |
| Pain in extremity           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 2 / 51 (3.92%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 2              | 1              |
| Tendonitis                  |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Arthritis                   |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Facet joint syndrome        |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Osteopenia                  |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Plantar fasciitis           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Ankle impingement           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Chondropathy                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Fistula                     |                |                |                |

|                              |                |                |                |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed  | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 0              | 0              | 0              |
| Joint stiffness              |                |                |                |
| subjects affected / exposed  | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 0              | 0              | 0              |
| Muscle contracture           |                |                |                |
| subjects affected / exposed  | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 0              | 0              | 0              |
| Muscle haemorrhage           |                |                |                |
| subjects affected / exposed  | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 0              | 0              | 0              |
| Muscular weakness            |                |                |                |
| subjects affected / exposed  | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 1              | 0              | 0              |
| Musculoskeletal chest pain   |                |                |                |
| subjects affected / exposed  | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 0              | 0              | 0              |
| Musculoskeletal discomfort   |                |                |                |
| subjects affected / exposed  | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)            | 0              | 0              | 1              |
| Musculoskeletal stiffness    |                |                |                |
| subjects affected / exposed  | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 0              | 0              | 0              |
| Myosclerosis                 |                |                |                |
| subjects affected / exposed  | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 0              | 0              | 0              |
| Neck pain                    |                |                |                |
| subjects affected / exposed  | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 0              | 0              | 0              |
| Osteoarthritis               |                |                |                |
| subjects affected / exposed  | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 1              | 0              | 0              |
| Patellofemoral pain syndrome |                |                |                |
| subjects affected / exposed  | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)            | 0              | 0              | 0              |
| Rheumatoid arthritis         |                |                |                |

|                                         |                 |                 |                 |
|-----------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed             | 0 / 53 (0.00%)  | 1 / 51 (1.96%)  | 0 / 51 (0.00%)  |
| occurrences (all)                       | 0               | 1               | 0               |
| Rotator cuff syndrome                   |                 |                 |                 |
| subjects affected / exposed             | 0 / 53 (0.00%)  | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)                       | 0               | 0               | 0               |
| Synovitis                               |                 |                 |                 |
| subjects affected / exposed             | 0 / 53 (0.00%)  | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)                       | 0               | 0               | 0               |
| Temporomandibular joint syndrome        |                 |                 |                 |
| subjects affected / exposed             | 0 / 53 (0.00%)  | 0 / 51 (0.00%)  | 0 / 51 (0.00%)  |
| occurrences (all)                       | 0               | 0               | 0               |
| Infections and infestations             |                 |                 |                 |
| Viral upper respiratory tract infection |                 |                 |                 |
| subjects affected / exposed             | 7 / 53 (13.21%) | 7 / 51 (13.73%) | 6 / 51 (11.76%) |
| occurrences (all)                       | 10              | 10              | 10              |
| Bronchitis                              |                 |                 |                 |
| subjects affected / exposed             | 5 / 53 (9.43%)  | 2 / 51 (3.92%)  | 2 / 51 (3.92%)  |
| occurrences (all)                       | 7               | 3               | 3               |
| Influenza                               |                 |                 |                 |
| subjects affected / exposed             | 5 / 53 (9.43%)  | 5 / 51 (9.80%)  | 4 / 51 (7.84%)  |
| occurrences (all)                       | 5               | 6               | 4               |
| Syphilis                                |                 |                 |                 |
| subjects affected / exposed             | 1 / 53 (1.89%)  | 3 / 51 (5.88%)  | 1 / 51 (1.96%)  |
| occurrences (all)                       | 1               | 3               | 1               |
| Respiratory tract infection             |                 |                 |                 |
| subjects affected / exposed             | 4 / 53 (7.55%)  | 1 / 51 (1.96%)  | 2 / 51 (3.92%)  |
| occurrences (all)                       | 6               | 2               | 3               |
| Upper respiratory tract infection       |                 |                 |                 |
| subjects affected / exposed             | 2 / 53 (3.77%)  | 3 / 51 (5.88%)  | 6 / 51 (11.76%) |
| occurrences (all)                       | 2               | 4               | 8               |
| Sinusitis                               |                 |                 |                 |
| subjects affected / exposed             | 2 / 53 (3.77%)  | 2 / 51 (3.92%)  | 3 / 51 (5.88%)  |
| occurrences (all)                       | 3               | 3               | 4               |
| Pharyngitis                             |                 |                 |                 |
| subjects affected / exposed             | 3 / 53 (5.66%)  | 3 / 51 (5.88%)  | 1 / 51 (1.96%)  |
| occurrences (all)                       | 3               | 3               | 1               |

|                                   |                |                |                |
|-----------------------------------|----------------|----------------|----------------|
| Gastroenteritis                   |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 2 / 51 (3.92%) |
| occurrences (all)                 | 0              | 1              | 2              |
| Rhinitis                          |                |                |                |
| subjects affected / exposed       | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 2 / 51 (3.92%) |
| occurrences (all)                 | 1              | 0              | 2              |
| Tonsillitis                       |                |                |                |
| subjects affected / exposed       | 3 / 53 (5.66%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 10             | 1              | 0              |
| Oral herpes                       |                |                |                |
| subjects affected / exposed       | 4 / 53 (7.55%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 4              | 1              | 0              |
| Respiratory tract infection viral |                |                |                |
| subjects affected / exposed       | 3 / 53 (5.66%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 4              | 4              | 0              |
| Folliculitis                      |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)                 | 0              | 1              | 1              |
| Herpes simplex                    |                |                |                |
| subjects affected / exposed       | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                 | 1              | 0              | 1              |
| Tooth abscess                     |                |                |                |
| subjects affected / exposed       | 2 / 53 (3.77%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)                 | 2              | 1              | 1              |
| Tooth infection                   |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 2 / 51 (3.92%) | 1 / 51 (1.96%) |
| occurrences (all)                 | 0              | 3              | 1              |
| Urinary tract infection           |                |                |                |
| subjects affected / exposed       | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 2 / 51 (3.92%) |
| occurrences (all)                 | 1              | 0              | 2              |
| Viral infection                   |                |                |                |
| subjects affected / exposed       | 1 / 53 (1.89%) | 3 / 51 (5.88%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 1              | 3              | 0              |
| Cellulitis                        |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)                 | 0              | 1              | 1              |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| Fungal skin infection       |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)           | 1              | 1              | 2              |
| Herpes zoster               |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)           | 1              | 1              | 1              |
| Acarodermatitis             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Chlamydial infection        |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Conjunctivitis              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 2 / 51 (3.92%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 2              | 1              |
| Ear infection               |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Furuncle                    |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 2 / 51 (3.92%) |
| occurrences (all)           | 1              | 0              | 3              |
| Gonorrhoea                  |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Onychomycosis               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Otitis media                |                |                |                |
| subjects affected / exposed | 3 / 53 (5.66%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 4              | 0              | 0              |
| Urethritis                  |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Gastroenteritis viral       |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| Herpes virus infection      |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Nasopharyngitis             |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Pharyngitis streptococcal   |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 1              | 1              |
| Tinea pedis                 |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 1              | 0              | 1              |
| Amoebic dysentery           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Angular cheilitis           |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Bacteriuria                 |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 1              | 0              | 1              |
| Body tinea                  |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Cystitis                    |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 1              | 0              |
| Dermatophytosis             |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Diverticulitis              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Fungal infection            |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 2              | 0              |

|                                |                |                |                |
|--------------------------------|----------------|----------------|----------------|
| Genital herpes                 |                |                |                |
| subjects affected / exposed    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 2 / 51 (3.92%) |
| occurrences (all)              | 0              | 0              | 2              |
| Giardiasis                     |                |                |                |
| subjects affected / exposed    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)              | 0              | 0              | 1              |
| Hepatitis C                    |                |                |                |
| subjects affected / exposed    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Laryngitis                     |                |                |                |
| subjects affected / exposed    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)              | 0              | 0              | 1              |
| Molluscum contagiosum          |                |                |                |
| subjects affected / exposed    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 2 / 51 (3.92%) |
| occurrences (all)              | 0              | 0              | 2              |
| Otitis externa                 |                |                |                |
| subjects affected / exposed    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Papilloma viral infection      |                |                |                |
| subjects affected / exposed    | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)              | 1              | 0              | 1              |
| Shigella infection             |                |                |                |
| subjects affected / exposed    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Staphylococcal infection       |                |                |                |
| subjects affected / exposed    | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)              | 0              | 2              | 0              |
| Subcutaneous abscess           |                |                |                |
| subjects affected / exposed    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Superinfection bacterial       |                |                |                |
| subjects affected / exposed    | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Vulvovaginal mycotic infection |                |                |                |
| subjects affected / exposed    | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)              | 1              | 0              | 0              |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| Acute hepatitis C           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Acute sinusitis             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Anal abscess                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 2              | 0              |
| Anal infection              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Anorectal infection         |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Candida infection           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 1              |
| Endometritis                |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 2              | 0              | 0              |
| Enterocolitis viral         |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Epididymitis                |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| External ear cellulitis     |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Febrile infection           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Gastritis viral             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |

|                                   |                |                |                |
|-----------------------------------|----------------|----------------|----------------|
| Gastroenteritis shigella          |                |                |                |
| subjects affected / exposed       | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 1              | 0              | 0              |
| Genital herpes simplex            |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Genital infection fungal          |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                 | 0              | 0              | 1              |
| Genitourinary chlamydia infection |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Gingivitis                        |                |                |                |
| subjects affected / exposed       | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 1              | 0              | 0              |
| Helicobacter infection            |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                 | 0              | 0              | 1              |
| Impetigo                          |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Infection                         |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Joint abscess                     |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 0              | 1              | 0              |
| Lower respiratory tract infection |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Lymphogranuloma venereum          |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Neurosyphilis                     |                |                |                |
| subjects affected / exposed       | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                 | 0              | 1              | 0              |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| Paronychia                  |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Periodontitis               |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Pilonidal cyst              |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Pneumonia                   |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Primary syphilis            |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Proctitis gonococcal        |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Pulpitis dental             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Pyelonephritis acute        |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Rash pustular               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Rubella                     |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Secondary syphilis          |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Sialoadenitis               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |

|                                    |                |                |                |
|------------------------------------|----------------|----------------|----------------|
| Skin candida                       |                |                |                |
| subjects affected / exposed        | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 1              | 0              | 0              |
| Staphylococcal skin infection      |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 0              | 0              | 0              |
| Tinea cruris                       |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 0              | 1              | 0              |
| Tinea infection                    |                |                |                |
| subjects affected / exposed        | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 2              | 0              | 0              |
| Toxocariasis                       |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                  | 0              | 0              | 1              |
| Urethritis gonococcal              |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 0              | 1              | 0              |
| Urinary tract infection bacterial  |                |                |                |
| subjects affected / exposed        | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 2              | 0              | 0              |
| Vaginal infection                  |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 0              | 0              | 0              |
| Viral pharyngitis                  |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)                  | 0              | 0              | 0              |
| Vulvovaginal candidiasis           |                |                |                |
| subjects affected / exposed        | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                  | 0              | 0              | 1              |
| Metabolism and nutrition disorders |                |                |                |
| Vitamin D deficiency               |                |                |                |
| subjects affected / exposed        | 2 / 53 (3.77%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)                  | 2              | 0              | 1              |
| Hyperglycaemia                     |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 2 / 53 (3.77%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 2              | 0              | 1              |
| Hyperlipidaemia             |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 0              | 2              |
| Decreased appetite          |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 1 / 51 (1.96%) |
| occurrences (all)           | 0              | 1              | 1              |
| Gout                        |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Hypercholesterolaemia       |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 2 / 51 (3.92%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 4              | 0              |
| Hyperinsulinaemia           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Diabetes mellitus           |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Fat redistribution          |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Fluid retention             |                |                |                |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Hypertriglyceridaemia       |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Hyponatraemia               |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 0 / 51 (0.00%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Type 2 diabetes mellitus    |                |                |                |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 51 (1.96%) | 0 / 51 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |

| <b>Non-serious adverse events</b>                                   | EFV 600mg        | Open-label DTG 50 mg QD |  |
|---------------------------------------------------------------------|------------------|-------------------------|--|
| Total subjects affected by non-serious adverse events               |                  |                         |  |
| subjects affected / exposed                                         | 46 / 50 (92.00%) | 112 / 138 (81.16%)      |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                  |                         |  |
| Anogenital warts                                                    |                  |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)   | 2 / 138 (1.45%)         |  |
| occurrences (all)                                                   | 0                | 2                       |  |
| Melanocytic naevus                                                  |                  |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)   | 2 / 138 (1.45%)         |  |
| occurrences (all)                                                   | 0                | 2                       |  |
| Infected naevus                                                     |                  |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)   | 0 / 138 (0.00%)         |  |
| occurrences (all)                                                   | 0                | 0                       |  |
| Papilloma                                                           |                  |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)   | 0 / 138 (0.00%)         |  |
| occurrences (all)                                                   | 0                | 0                       |  |
| Prostatic adenoma                                                   |                  |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)   | 1 / 138 (0.72%)         |  |
| occurrences (all)                                                   | 0                | 1                       |  |
| Skin papilloma                                                      |                  |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)   | 0 / 138 (0.00%)         |  |
| occurrences (all)                                                   | 0                | 0                       |  |
| Vascular disorders                                                  |                  |                         |  |
| Hypertension                                                        |                  |                         |  |
| subjects affected / exposed                                         | 2 / 50 (4.00%)   | 2 / 138 (1.45%)         |  |
| occurrences (all)                                                   | 2                | 2                       |  |
| Aortic arteriosclerosis                                             |                  |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)   | 0 / 138 (0.00%)         |  |
| occurrences (all)                                                   | 0                | 0                       |  |
| Arterial fibrosis                                                   |                  |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)   | 0 / 138 (0.00%)         |  |
| occurrences (all)                                                   | 0                | 0                       |  |
| Hot flush                                                           |                  |                         |  |
| subjects affected / exposed                                         | 0 / 50 (0.00%)   | 1 / 138 (0.72%)         |  |
| occurrences (all)                                                   | 0                | 1                       |  |
| Peripheral coldness                                                 |                  |                         |  |

|                                                      |                 |                 |  |
|------------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed                          | 1 / 50 (2.00%)  | 0 / 138 (0.00%) |  |
| occurrences (all)                                    | 1               | 0               |  |
| Peripheral venous disease                            |                 |                 |  |
| subjects affected / exposed                          | 0 / 50 (0.00%)  | 1 / 138 (0.72%) |  |
| occurrences (all)                                    | 0               | 1               |  |
| Phlebitis                                            |                 |                 |  |
| subjects affected / exposed                          | 0 / 50 (0.00%)  | 1 / 138 (0.72%) |  |
| occurrences (all)                                    | 0               | 1               |  |
| General disorders and administration site conditions |                 |                 |  |
| Pyrexia                                              |                 |                 |  |
| subjects affected / exposed                          | 4 / 50 (8.00%)  | 6 / 138 (4.35%) |  |
| occurrences (all)                                    | 5               | 9               |  |
| Fatigue                                              |                 |                 |  |
| subjects affected / exposed                          | 6 / 50 (12.00%) | 3 / 138 (2.17%) |  |
| occurrences (all)                                    | 6               | 4               |  |
| Asthenia                                             |                 |                 |  |
| subjects affected / exposed                          | 0 / 50 (0.00%)  | 3 / 138 (2.17%) |  |
| occurrences (all)                                    | 0               | 3               |  |
| Influenza like illness                               |                 |                 |  |
| subjects affected / exposed                          | 1 / 50 (2.00%)  | 3 / 138 (2.17%) |  |
| occurrences (all)                                    | 1               | 3               |  |
| Chest pain                                           |                 |                 |  |
| subjects affected / exposed                          | 2 / 50 (4.00%)  | 2 / 138 (1.45%) |  |
| occurrences (all)                                    | 2               | 2               |  |
| Malaise                                              |                 |                 |  |
| subjects affected / exposed                          | 1 / 50 (2.00%)  | 2 / 138 (1.45%) |  |
| occurrences (all)                                    | 1               | 2               |  |
| Oedema peripheral                                    |                 |                 |  |
| subjects affected / exposed                          | 0 / 50 (0.00%)  | 2 / 138 (1.45%) |  |
| occurrences (all)                                    | 0               | 2               |  |
| Pain                                                 |                 |                 |  |
| subjects affected / exposed                          | 1 / 50 (2.00%)  | 1 / 138 (0.72%) |  |
| occurrences (all)                                    | 1               | 1               |  |
| Adverse drug reaction                                |                 |                 |  |

|                                       |                |                 |  |
|---------------------------------------|----------------|-----------------|--|
| subjects affected / exposed           | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                     | 0              | 0               |  |
| Chest discomfort                      |                |                 |  |
| subjects affected / exposed           | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                     | 0              | 0               |  |
| Drug intolerance                      |                |                 |  |
| subjects affected / exposed           | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                     | 1              | 0               |  |
| Feeling drunk                         |                |                 |  |
| subjects affected / exposed           | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                     | 1              | 0               |  |
| Feeling hot                           |                |                 |  |
| subjects affected / exposed           | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                     | 1              | 0               |  |
| General physical health deterioration |                |                 |  |
| subjects affected / exposed           | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                     | 1              | 0               |  |
| Injection site pain                   |                |                 |  |
| subjects affected / exposed           | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                     | 1              | 0               |  |
| Nodule                                |                |                 |  |
| subjects affected / exposed           | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                     | 0              | 0               |  |
| Oedema                                |                |                 |  |
| subjects affected / exposed           | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)                     | 0              | 1               |  |
| Immune system disorders               |                |                 |  |
| Seasonal allergy                      |                |                 |  |
| subjects affected / exposed           | 0 / 50 (0.00%) | 2 / 138 (1.45%) |  |
| occurrences (all)                     | 0              | 2               |  |
| Allergy to arthropod sting            |                |                 |  |
| subjects affected / exposed           | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                     | 0              | 0               |  |
| Drug hypersensitivity                 |                |                 |  |
| subjects affected / exposed           | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                     | 2              | 0               |  |

|                                          |                |                 |  |
|------------------------------------------|----------------|-----------------|--|
| Food allergy                             |                |                 |  |
| subjects affected / exposed              | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                        | 0              | 0               |  |
| Hypersensitivity                         |                |                 |  |
| subjects affected / exposed              | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)                        | 0              | 1               |  |
| Multiple allergies                       |                |                 |  |
| subjects affected / exposed              | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                        | 0              | 0               |  |
| Reproductive system and breast disorders |                |                 |  |
| Erectile dysfunction                     |                |                 |  |
| subjects affected / exposed              | 1 / 50 (2.00%) | 3 / 138 (2.17%) |  |
| occurrences (all)                        | 1              | 3               |  |
| Genital lesion                           |                |                 |  |
| subjects affected / exposed              | 1 / 50 (2.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)                        | 1              | 1               |  |
| Ovarian cyst                             |                |                 |  |
| subjects affected / exposed              | 1 / 50 (2.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)                        | 1              | 1               |  |
| Prostatitis                              |                |                 |  |
| subjects affected / exposed              | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                        | 0              | 0               |  |
| Breast discomfort                        |                |                 |  |
| subjects affected / exposed              | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)                        | 0              | 1               |  |
| Breast mass                              |                |                 |  |
| subjects affected / exposed              | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                        | 0              | 0               |  |
| Cervical dysplasia                       |                |                 |  |
| subjects affected / exposed              | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)                        | 0              | 1               |  |
| Gynaecomastia                            |                |                 |  |
| subjects affected / exposed              | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                        | 1              | 0               |  |
| Penile discharge                         |                |                 |  |

|                                                 |                |                  |  |
|-------------------------------------------------|----------------|------------------|--|
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%)  |  |
| occurrences (all)                               | 0              | 0                |  |
| Peyronie's disease                              |                |                  |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%)  |  |
| occurrences (all)                               | 0              | 0                |  |
| Respiratory, thoracic and mediastinal disorders |                |                  |  |
| Cough                                           |                |                  |  |
| subjects affected / exposed                     | 2 / 50 (4.00%) | 10 / 138 (7.25%) |  |
| occurrences (all)                               | 2              | 12               |  |
| Oropharyngeal pain                              |                |                  |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 5 / 138 (3.62%)  |  |
| occurrences (all)                               | 1              | 5                |  |
| Asthma                                          |                |                  |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 3 / 138 (2.17%)  |  |
| occurrences (all)                               | 0              | 3                |  |
| Sinus congestion                                |                |                  |  |
| subjects affected / exposed                     | 2 / 50 (4.00%) | 1 / 138 (0.72%)  |  |
| occurrences (all)                               | 2              | 1                |  |
| Dyspnoea                                        |                |                  |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 2 / 138 (1.45%)  |  |
| occurrences (all)                               | 0              | 5                |  |
| Rhinitis allergic                               |                |                  |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 1 / 138 (0.72%)  |  |
| occurrences (all)                               | 2              | 1                |  |
| Lung disorder                                   |                |                  |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 2 / 138 (1.45%)  |  |
| occurrences (all)                               | 0              | 3                |  |
| Respiratory disorder                            |                |                  |  |
| subjects affected / exposed                     | 1 / 50 (2.00%) | 0 / 138 (0.00%)  |  |
| occurrences (all)                               | 1              | 0                |  |
| Rhinorrhoea                                     |                |                  |  |
| subjects affected / exposed                     | 0 / 50 (0.00%) | 0 / 138 (0.00%)  |  |
| occurrences (all)                               | 0              | 0                |  |
| Asthmatic crisis                                |                |                  |  |

|                                    |                |                 |
|------------------------------------|----------------|-----------------|
| subjects affected / exposed        | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                  | 0              | 0               |
| Bronchitis chronic                 |                |                 |
| subjects affected / exposed        | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                  | 0              | 0               |
| Bronchopneumopathy                 |                |                 |
| subjects affected / exposed        | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                  | 0              | 1               |
| Dysphonia                          |                |                 |
| subjects affected / exposed        | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                  | 0              | 0               |
| Hyperventilation                   |                |                 |
| subjects affected / exposed        | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                  | 1              | 0               |
| Lower respiratory tract congestion |                |                 |
| subjects affected / exposed        | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                  | 0              | 0               |
| Nasal congestion                   |                |                 |
| subjects affected / exposed        | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                  | 0              | 0               |
| Pharyngeal disorder                |                |                 |
| subjects affected / exposed        | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                  | 0              | 0               |
| Respiratory tract congestion       |                |                 |
| subjects affected / exposed        | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                  | 0              | 0               |
| Sleep apnoea syndrome              |                |                 |
| subjects affected / exposed        | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                  | 0              | 1               |
| Snoring                            |                |                 |
| subjects affected / exposed        | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                  | 0              | 1               |
| Upper respiratory tract congestion |                |                 |
| subjects affected / exposed        | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                  | 1              | 0               |
| Upper-airway cough syndrome        |                |                 |

|                                                  |                     |                      |  |
|--------------------------------------------------|---------------------|----------------------|--|
| subjects affected / exposed<br>occurrences (all) | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Psychiatric disorders                            |                     |                      |  |
| Insomnia                                         |                     |                      |  |
| subjects affected / exposed                      | 6 / 50 (12.00%)     | 5 / 138 (3.62%)      |  |
| occurrences (all)                                | 6                   | 5                    |  |
| Depression                                       |                     |                      |  |
| subjects affected / exposed                      | 5 / 50 (10.00%)     | 6 / 138 (4.35%)      |  |
| occurrences (all)                                | 5                   | 6                    |  |
| Anxiety                                          |                     |                      |  |
| subjects affected / exposed                      | 3 / 50 (6.00%)      | 4 / 138 (2.90%)      |  |
| occurrences (all)                                | 3                   | 4                    |  |
| Abnormal dreams                                  |                     |                      |  |
| subjects affected / exposed                      | 3 / 50 (6.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 3                   | 0                    |  |
| Nightmare                                        |                     |                      |  |
| subjects affected / exposed                      | 4 / 50 (8.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 4                   | 0                    |  |
| Stress                                           |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 1 / 138 (0.72%)      |  |
| occurrences (all)                                | 0                   | 1                    |  |
| Acute stress disorder                            |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 1 / 138 (0.72%)      |  |
| occurrences (all)                                | 0                   | 1                    |  |
| Loss of libido                                   |                     |                      |  |
| subjects affected / exposed                      | 1 / 50 (2.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                    |  |
| Sleep disorder                                   |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 1 / 138 (0.72%)      |  |
| occurrences (all)                                | 0                   | 1                    |  |
| Affect lability                                  |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Anxiety disorder                                 |                     |                      |  |
| subjects affected / exposed                      | 1 / 50 (2.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                    |  |

|                                        |                |                 |  |
|----------------------------------------|----------------|-----------------|--|
| Bulimia nervosa                        |                |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 0              | 0               |  |
| Disorientation                         |                |                 |  |
| subjects affected / exposed            | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 1              | 0               |  |
| Hallucination                          |                |                 |  |
| subjects affected / exposed            | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 1              | 0               |  |
| Libido increased                       |                |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 0              | 0               |  |
| Listless                               |                |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 0              | 0               |  |
| Mental disorder                        |                |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 0              | 0               |  |
| Panic attack                           |                |                 |  |
| subjects affected / exposed            | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 2              | 0               |  |
| Post-traumatic stress disorder         |                |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)                      | 0              | 1               |  |
| Substance use disorder                 |                |                 |  |
| subjects affected / exposed            | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 1              | 0               |  |
| Investigations                         |                |                 |  |
| Blood creatine phosphokinase increased |                |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)                      | 0              | 1               |  |
| Blood cholesterol increased            |                |                 |  |
| subjects affected / exposed            | 1 / 50 (2.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)                      | 1              | 1               |  |
| Alanine aminotransferase increased     |                |                 |  |

|                                              |                |                 |
|----------------------------------------------|----------------|-----------------|
| subjects affected / exposed                  | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                            | 0              | 0               |
| Blood glucose increased                      |                |                 |
| subjects affected / exposed                  | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                            | 1              | 0               |
| Lipase increased                             |                |                 |
| subjects affected / exposed                  | 0 / 50 (0.00%) | 2 / 138 (1.45%) |
| occurrences (all)                            | 0              | 2               |
| Amylase increased                            |                |                 |
| subjects affected / exposed                  | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                            | 0              | 1               |
| Anal pap smear abnormal                      |                |                 |
| subjects affected / exposed                  | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                            | 0              | 0               |
| Bacterial test positive                      |                |                 |
| subjects affected / exposed                  | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                            | 0              | 1               |
| Blood creatinine increased                   |                |                 |
| subjects affected / exposed                  | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                            | 0              | 0               |
| Cardiac murmur                               |                |                 |
| subjects affected / exposed                  | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                            | 1              | 0               |
| Electrocardiogram repolarisation abnormality |                |                 |
| subjects affected / exposed                  | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                            | 0              | 0               |
| Liver function test increased                |                |                 |
| subjects affected / exposed                  | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                            | 1              | 0               |
| Neutrophil count decreased                   |                |                 |
| subjects affected / exposed                  | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                            | 0              | 0               |
| Transaminases increased                      |                |                 |
| subjects affected / exposed                  | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                            | 0              | 0               |

|                                                                              |                     |                      |  |
|------------------------------------------------------------------------------|---------------------|----------------------|--|
| Urinary sediment present<br>subjects affected / exposed<br>occurrences (all) | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Weight decreased<br>subjects affected / exposed<br>occurrences (all)         | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Weight increased<br>subjects affected / exposed<br>occurrences (all)         | 1 / 50 (2.00%)<br>1 | 0 / 138 (0.00%)<br>0 |  |
| Injury, poisoning and procedural complications                               |                     |                      |  |
| Ligament sprain<br>subjects affected / exposed<br>occurrences (all)          | 0 / 50 (0.00%)<br>0 | 3 / 138 (2.17%)<br>5 |  |
| Concussion<br>subjects affected / exposed<br>occurrences (all)               | 0 / 50 (0.00%)<br>0 | 2 / 138 (1.45%)<br>2 |  |
| Contusion<br>subjects affected / exposed<br>occurrences (all)                | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Laceration<br>subjects affected / exposed<br>occurrences (all)               | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Limb injury<br>subjects affected / exposed<br>occurrences (all)              | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Muscle strain<br>subjects affected / exposed<br>occurrences (all)            | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Procedural pain<br>subjects affected / exposed<br>occurrences (all)          | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Anal injury<br>subjects affected / exposed<br>occurrences (all)              | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Cervical vertebral fracture                                                  |                     |                      |  |

|                             |                |                 |
|-----------------------------|----------------|-----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Clavicle fracture           |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Epicondylitis               |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Face injury                 |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Fall                        |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Foot fracture               |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Joint dislocation           |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Rib fracture                |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Scrotal haematoma           |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Stress fracture             |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Tendon rupture              |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Vaccination complication    |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Wrist fracture              |                |                 |

|                                                  |                     |                      |  |
|--------------------------------------------------|---------------------|----------------------|--|
| subjects affected / exposed<br>occurrences (all) | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Cardiac disorders                                |                     |                      |  |
| Sinus tachycardia                                |                     |                      |  |
| subjects affected / exposed                      | 1 / 50 (2.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                    |  |
| Tachycardia                                      |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 1 / 138 (0.72%)      |  |
| occurrences (all)                                | 0                   | 1                    |  |
| Aortic valve incompetence                        |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Arrhythmia                                       |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 1 / 138 (0.72%)      |  |
| occurrences (all)                                | 0                   | 1                    |  |
| Bradycardia                                      |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Cardiomegaly                                     |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Palpitations                                     |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Nervous system disorders                         |                     |                      |  |
| Headache                                         |                     |                      |  |
| subjects affected / exposed                      | 3 / 50 (6.00%)      | 8 / 138 (5.80%)      |  |
| occurrences (all)                                | 5                   | 10                   |  |
| Dizziness                                        |                     |                      |  |
| subjects affected / exposed                      | 11 / 50 (22.00%)    | 2 / 138 (1.45%)      |  |
| occurrences (all)                                | 13                  | 2                    |  |
| Paraesthesia                                     |                     |                      |  |
| subjects affected / exposed                      | 2 / 50 (4.00%)      | 3 / 138 (2.17%)      |  |
| occurrences (all)                                | 2                   | 3                    |  |
| Somnolence                                       |                     |                      |  |

|                             |                |                 |
|-----------------------------|----------------|-----------------|
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 2              | 0               |
| Dysgeusia                   |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Memory impairment           |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Sciatica                    |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 2 / 138 (1.45%) |
| occurrences (all)           | 1              | 3               |
| Hypoaesthesia               |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Poor quality sleep          |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Restless legs syndrome      |                |                 |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 2              | 0               |
| Syncope                     |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Ageusia                     |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Anosmia                     |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Cervical radiculopathy      |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Cluster headache            |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Cognitive disorder          |                |                 |

|                                      |                |                 |
|--------------------------------------|----------------|-----------------|
| subjects affected / exposed          | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                    | 0              | 1               |
| Hyperaesthesia                       |                |                 |
| subjects affected / exposed          | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                    | 0              | 0               |
| Hypertonia                           |                |                 |
| subjects affected / exposed          | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                    | 0              | 1               |
| Migraine                             |                |                 |
| subjects affected / exposed          | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                    | 0              | 1               |
| Neuropathy peripheral                |                |                 |
| subjects affected / exposed          | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                    | 0              | 0               |
| Post herpetic neuralgia              |                |                 |
| subjects affected / exposed          | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                    | 0              | 0               |
| Presyncope                           |                |                 |
| subjects affected / exposed          | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                    | 1              | 0               |
| Sinus headache                       |                |                 |
| subjects affected / exposed          | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                    | 0              | 0               |
| Tongue biting                        |                |                 |
| subjects affected / exposed          | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                    | 0              | 0               |
| Tremor                               |                |                 |
| subjects affected / exposed          | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                    | 0              | 0               |
| Trigeminal neuralgia                 |                |                 |
| subjects affected / exposed          | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                    | 0              | 1               |
| Visual field defect                  |                |                 |
| subjects affected / exposed          | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                    | 1              | 0               |
| Blood and lymphatic system disorders |                |                 |

|                                                                             |                     |                      |  |
|-----------------------------------------------------------------------------|---------------------|----------------------|--|
| Lymphadenopathy<br>subjects affected / exposed<br>occurrences (all)         | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)             | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Iron deficiency anaemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Lymphadenitis<br>subjects affected / exposed<br>occurrences (all)           | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Ear and labyrinth disorders                                                 |                     |                      |  |
| Vertigo<br>subjects affected / exposed<br>occurrences (all)                 | 2 / 50 (4.00%)<br>2 | 0 / 138 (0.00%)<br>0 |  |
| Tinnitus<br>subjects affected / exposed<br>occurrences (all)                | 1 / 50 (2.00%)<br>1 | 2 / 138 (1.45%)<br>2 |  |
| Ear pain<br>subjects affected / exposed<br>occurrences (all)                | 1 / 50 (2.00%)<br>1 | 0 / 138 (0.00%)<br>0 |  |
| Hypoacusis<br>subjects affected / exposed<br>occurrences (all)              | 2 / 50 (4.00%)<br>2 | 0 / 138 (0.00%)<br>0 |  |
| Cerumen impaction<br>subjects affected / exposed<br>occurrences (all)       | 1 / 50 (2.00%)<br>1 | 0 / 138 (0.00%)<br>0 |  |
| Ear congestion<br>subjects affected / exposed<br>occurrences (all)          | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Ear pruritus<br>subjects affected / exposed<br>occurrences (all)            | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Presbycusis                                                                 |                     |                      |  |

|                                                  |                     |                      |  |
|--------------------------------------------------|---------------------|----------------------|--|
| subjects affected / exposed<br>occurrences (all) | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Eye disorders                                    |                     |                      |  |
| Astigmatism                                      |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Chalazion                                        |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 1 / 138 (0.72%)      |  |
| occurrences (all)                                | 0                   | 1                    |  |
| Dark circles under eyes                          |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Myopia                                           |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Vision blurred                                   |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Visual acuity reduced                            |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 1 / 138 (0.72%)      |  |
| occurrences (all)                                | 0                   | 1                    |  |
| Vitreous floaters                                |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Gastrointestinal disorders                       |                     |                      |  |
| Diarrhoea                                        |                     |                      |  |
| subjects affected / exposed                      | 5 / 50 (10.00%)     | 12 / 138 (8.70%)     |  |
| occurrences (all)                                | 7                   | 14                   |  |
| Nausea                                           |                     |                      |  |
| subjects affected / exposed                      | 7 / 50 (14.00%)     | 2 / 138 (1.45%)      |  |
| occurrences (all)                                | 7                   | 2                    |  |
| Haemorrhoids                                     |                     |                      |  |
| subjects affected / exposed                      | 2 / 50 (4.00%)      | 8 / 138 (5.80%)      |  |
| occurrences (all)                                | 2                   | 10                   |  |
| Abdominal pain                                   |                     |                      |  |

|                                  |                |                 |
|----------------------------------|----------------|-----------------|
| subjects affected / exposed      | 1 / 50 (2.00%) | 3 / 138 (2.17%) |
| occurrences (all)                | 1              | 3               |
| Dyspepsia                        |                |                 |
| subjects affected / exposed      | 2 / 50 (4.00%) | 3 / 138 (2.17%) |
| occurrences (all)                | 2              | 3               |
| Abdominal pain upper             |                |                 |
| subjects affected / exposed      | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                | 1              | 0               |
| Gastrooesophageal reflux disease |                |                 |
| subjects affected / exposed      | 2 / 50 (4.00%) | 5 / 138 (3.62%) |
| occurrences (all)                | 2              | 5               |
| Vomiting                         |                |                 |
| subjects affected / exposed      | 1 / 50 (2.00%) | 1 / 138 (0.72%) |
| occurrences (all)                | 1              | 1               |
| Toothache                        |                |                 |
| subjects affected / exposed      | 1 / 50 (2.00%) | 1 / 138 (0.72%) |
| occurrences (all)                | 1              | 2               |
| Gastritis                        |                |                 |
| subjects affected / exposed      | 1 / 50 (2.00%) | 3 / 138 (2.17%) |
| occurrences (all)                | 1              | 3               |
| Abdominal discomfort             |                |                 |
| subjects affected / exposed      | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                | 1              | 0               |
| Constipation                     |                |                 |
| subjects affected / exposed      | 0 / 50 (0.00%) | 2 / 138 (1.45%) |
| occurrences (all)                | 0              | 2               |
| Proctitis                        |                |                 |
| subjects affected / exposed      | 0 / 50 (0.00%) | 3 / 138 (2.17%) |
| occurrences (all)                | 0              | 4               |
| Faeces soft                      |                |                 |
| subjects affected / exposed      | 2 / 50 (4.00%) | 0 / 138 (0.00%) |
| occurrences (all)                | 2              | 0               |
| Haematochezia                    |                |                 |
| subjects affected / exposed      | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                | 0              | 1               |
| Anal fissure                     |                |                 |

|                             |                |                 |
|-----------------------------|----------------|-----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 2 / 138 (1.45%) |
| occurrences (all)           | 0              | 2               |
| Anal fistula                |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 2 / 138 (1.45%) |
| occurrences (all)           | 0              | 2               |
| Anogenital dysplasia        |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Aphthous ulcer              |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Epigastric discomfort       |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Flatulence                  |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Inguinal hernia             |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Rectal haemorrhage          |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Abdominal distension        |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Abdominal pain lower        |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Anal pruritus               |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Anal skin tags              |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Anal sphincter hypertonia   |                |                 |

|                             |                |                 |
|-----------------------------|----------------|-----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Anal ulcer                  |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Anorectal disorder          |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Anorectal ulcer             |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Change of bowel habit       |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Chronic gastritis           |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Dental caries               |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Enteritis                   |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 3               |
| Enterocolitis               |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Food poisoning              |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 2              | 0               |
| Gastrointestinal disorder   |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Hiatus hernia               |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Hypoaesthesia oral          |                |                 |

|                             |                |                 |  |
|-----------------------------|----------------|-----------------|--|
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)           | 0              | 1               |  |
| Intestinal polyp            |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)           | 0              | 1               |  |
| Leukoplakia oral            |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)           | 0              | 0               |  |
| Odynophagia                 |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)           | 0              | 0               |  |
| Pancreatic atrophy          |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)           | 0              | 1               |  |
| Perianal erythema           |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)           | 0              | 1               |  |
| Rectal polyp                |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)           | 0              | 1               |  |
| Stomatitis                  |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)           | 0              | 0               |  |
| Tongue discolouration       |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)           | 0              | 0               |  |
| Tongue disorder             |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)           | 0              | 1               |  |
| Umbilical hernia            |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)           | 0              | 1               |  |
| Hepatobiliary disorders     |                |                 |  |
| Hypertransaminasaemia       |                |                 |  |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)           | 1              | 1               |  |

|                                        |                 |                 |  |
|----------------------------------------|-----------------|-----------------|--|
| Hepatic steatosis                      |                 |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%)  | 2 / 138 (1.45%) |  |
| occurrences (all)                      | 0               | 2               |  |
| Cholestasis                            |                 |                 |  |
| subjects affected / exposed            | 1 / 50 (2.00%)  | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 1               | 0               |  |
| Skin and subcutaneous tissue disorders |                 |                 |  |
| Rash                                   |                 |                 |  |
| subjects affected / exposed            | 6 / 50 (12.00%) | 2 / 138 (1.45%) |  |
| occurrences (all)                      | 6               | 2               |  |
| Pruritus                               |                 |                 |  |
| subjects affected / exposed            | 3 / 50 (6.00%)  | 3 / 138 (2.17%) |  |
| occurrences (all)                      | 3               | 3               |  |
| Dermatitis                             |                 |                 |  |
| subjects affected / exposed            | 1 / 50 (2.00%)  | 1 / 138 (0.72%) |  |
| occurrences (all)                      | 1               | 1               |  |
| Alopecia                               |                 |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%)  | 1 / 138 (0.72%) |  |
| occurrences (all)                      | 0               | 1               |  |
| Eczema                                 |                 |                 |  |
| subjects affected / exposed            | 1 / 50 (2.00%)  | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 1               | 0               |  |
| Night sweats                           |                 |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%)  | 0 / 138 (0.00%) |  |
| occurrences (all)                      | 0               | 0               |  |
| Urticaria                              |                 |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%)  | 2 / 138 (1.45%) |  |
| occurrences (all)                      | 0               | 2               |  |
| Erythema                               |                 |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%)  | 1 / 138 (0.72%) |  |
| occurrences (all)                      | 0               | 1               |  |
| Hyperhidrosis                          |                 |                 |  |
| subjects affected / exposed            | 0 / 50 (0.00%)  | 1 / 138 (0.72%) |  |
| occurrences (all)                      | 0               | 4               |  |
| Photosensitivity reaction              |                 |                 |  |

|                             |                |                 |
|-----------------------------|----------------|-----------------|
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Dry skin                    |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Hyperkeratosis              |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Prurigo                     |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 2               |
| Seborrhoeic dermatitis      |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Skin hyperpigmentation      |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Actinic keratosis           |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Blister                     |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Dermal cyst                 |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Hand dermatitis             |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Intertrigo                  |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Lipoatrophy                 |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Miliaria                    |                |                 |

|                             |                |                 |
|-----------------------------|----------------|-----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Palmar erythema             |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Pigmentation disorder       |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Pruritus generalised        |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Psoriasis                   |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Rash macular                |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Rash maculo-papular         |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Rash papular                |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Rash pruritic               |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Skin erosion                |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Skin lesion                 |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Solar dermatitis            |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Toxic skin eruption         |                |                 |

|                                                  |                     |                      |  |
|--------------------------------------------------|---------------------|----------------------|--|
| subjects affected / exposed<br>occurrences (all) | 1 / 50 (2.00%)<br>1 | 0 / 138 (0.00%)<br>0 |  |
| Renal and urinary disorders                      |                     |                      |  |
| Dysuria                                          |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 3 / 138 (2.17%)      |  |
| occurrences (all)                                | 0                   | 4                    |  |
| Proteinuria                                      |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 2 / 138 (1.45%)      |  |
| occurrences (all)                                | 0                   | 2                    |  |
| Nephrolithiasis                                  |                     |                      |  |
| subjects affected / exposed                      | 1 / 50 (2.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                    |  |
| Haematuria                                       |                     |                      |  |
| subjects affected / exposed                      | 1 / 50 (2.00%)      | 1 / 138 (0.72%)      |  |
| occurrences (all)                                | 1                   | 1                    |  |
| Pollakiuria                                      |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 2 / 138 (1.45%)      |  |
| occurrences (all)                                | 0                   | 2                    |  |
| Leukocyturia                                     |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Acute kidney injury                              |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Chronic kidney disease                           |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |
| Micturition urgency                              |                     |                      |  |
| subjects affected / exposed                      | 1 / 50 (2.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 1                   | 0                    |  |
| Urethral discharge                               |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 1 / 138 (0.72%)      |  |
| occurrences (all)                                | 0                   | 1                    |  |
| Urethritis noninfective                          |                     |                      |  |
| subjects affected / exposed                      | 0 / 50 (0.00%)      | 0 / 138 (0.00%)      |  |
| occurrences (all)                                | 0                   | 0                    |  |

|                                                                          |                     |                        |  |
|--------------------------------------------------------------------------|---------------------|------------------------|--|
| Urinary hesitation<br>subjects affected / exposed<br>occurrences (all)   | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1   |  |
| Endocrine disorders                                                      |                     |                        |  |
| Hypogonadism<br>subjects affected / exposed<br>occurrences (all)         | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0   |  |
| Hypothyroidism<br>subjects affected / exposed<br>occurrences (all)       | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1   |  |
| Goitre<br>subjects affected / exposed<br>occurrences (all)               | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0   |  |
| Musculoskeletal and connective tissue disorders                          |                     |                        |  |
| Back pain<br>subjects affected / exposed<br>occurrences (all)            | 4 / 50 (8.00%)<br>5 | 10 / 138 (7.25%)<br>10 |  |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)           | 1 / 50 (2.00%)<br>1 | 5 / 138 (3.62%)<br>5   |  |
| Musculoskeletal pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1   |  |
| Myalgia<br>subjects affected / exposed<br>occurrences (all)              | 1 / 50 (2.00%)<br>1 | 2 / 138 (1.45%)<br>2   |  |
| Muscle spasms<br>subjects affected / exposed<br>occurrences (all)        | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1   |  |
| Exostosis<br>subjects affected / exposed<br>occurrences (all)            | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1   |  |
| Pain in extremity<br>subjects affected / exposed<br>occurrences (all)    | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1   |  |
| Tendonitis                                                               |                     |                        |  |

|                             |                |                 |
|-----------------------------|----------------|-----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 4 / 138 (2.90%) |
| occurrences (all)           | 0              | 6               |
| Arthritis                   |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Facet joint syndrome        |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Osteopenia                  |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 1              | 1               |
| Plantar fasciitis           |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Ankle impingement           |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Chondropathy                |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Fistula                     |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 3              | 0               |
| Joint stiffness             |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Muscle contracture          |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Muscle haemorrhage          |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Muscular weakness           |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Musculoskeletal chest pain  |                |                 |

|                                         |                 |                   |  |
|-----------------------------------------|-----------------|-------------------|--|
| subjects affected / exposed             | 0 / 50 (0.00%)  | 1 / 138 (0.72%)   |  |
| occurrences (all)                       | 0               | 1                 |  |
| Musculoskeletal discomfort              |                 |                   |  |
| subjects affected / exposed             | 0 / 50 (0.00%)  | 0 / 138 (0.00%)   |  |
| occurrences (all)                       | 0               | 0                 |  |
| Musculoskeletal stiffness               |                 |                   |  |
| subjects affected / exposed             | 0 / 50 (0.00%)  | 1 / 138 (0.72%)   |  |
| occurrences (all)                       | 0               | 1                 |  |
| Myosclerosis                            |                 |                   |  |
| subjects affected / exposed             | 1 / 50 (2.00%)  | 0 / 138 (0.00%)   |  |
| occurrences (all)                       | 1               | 0                 |  |
| Neck pain                               |                 |                   |  |
| subjects affected / exposed             | 0 / 50 (0.00%)  | 1 / 138 (0.72%)   |  |
| occurrences (all)                       | 0               | 1                 |  |
| Osteoarthritis                          |                 |                   |  |
| subjects affected / exposed             | 0 / 50 (0.00%)  | 0 / 138 (0.00%)   |  |
| occurrences (all)                       | 0               | 0                 |  |
| Patellofemoral pain syndrome            |                 |                   |  |
| subjects affected / exposed             | 1 / 50 (2.00%)  | 0 / 138 (0.00%)   |  |
| occurrences (all)                       | 1               | 0                 |  |
| Rheumatoid arthritis                    |                 |                   |  |
| subjects affected / exposed             | 0 / 50 (0.00%)  | 0 / 138 (0.00%)   |  |
| occurrences (all)                       | 0               | 0                 |  |
| Rotator cuff syndrome                   |                 |                   |  |
| subjects affected / exposed             | 0 / 50 (0.00%)  | 1 / 138 (0.72%)   |  |
| occurrences (all)                       | 0               | 1                 |  |
| Synovitis                               |                 |                   |  |
| subjects affected / exposed             | 0 / 50 (0.00%)  | 1 / 138 (0.72%)   |  |
| occurrences (all)                       | 0               | 1                 |  |
| Temporomandibular joint syndrome        |                 |                   |  |
| subjects affected / exposed             | 0 / 50 (0.00%)  | 1 / 138 (0.72%)   |  |
| occurrences (all)                       | 0               | 1                 |  |
| Infections and infestations             |                 |                   |  |
| Viral upper respiratory tract infection |                 |                   |  |
| subjects affected / exposed             | 5 / 50 (10.00%) | 20 / 138 (14.49%) |  |
| occurrences (all)                       | 7               | 27                |  |

|                                   |                 |                  |
|-----------------------------------|-----------------|------------------|
| Bronchitis                        |                 |                  |
| subjects affected / exposed       | 5 / 50 (10.00%) | 10 / 138 (7.25%) |
| occurrences (all)                 | 6               | 14               |
| Influenza                         |                 |                  |
| subjects affected / exposed       | 3 / 50 (6.00%)  | 6 / 138 (4.35%)  |
| occurrences (all)                 | 3               | 9                |
| Syphilis                          |                 |                  |
| subjects affected / exposed       | 4 / 50 (8.00%)  | 12 / 138 (8.70%) |
| occurrences (all)                 | 4               | 15               |
| Respiratory tract infection       |                 |                  |
| subjects affected / exposed       | 3 / 50 (6.00%)  | 9 / 138 (6.52%)  |
| occurrences (all)                 | 4               | 13               |
| Upper respiratory tract infection |                 |                  |
| subjects affected / exposed       | 1 / 50 (2.00%)  | 7 / 138 (5.07%)  |
| occurrences (all)                 | 1               | 10               |
| Sinusitis                         |                 |                  |
| subjects affected / exposed       | 4 / 50 (8.00%)  | 6 / 138 (4.35%)  |
| occurrences (all)                 | 6               | 6                |
| Pharyngitis                       |                 |                  |
| subjects affected / exposed       | 2 / 50 (4.00%)  | 3 / 138 (2.17%)  |
| occurrences (all)                 | 2               | 3                |
| Gastroenteritis                   |                 |                  |
| subjects affected / exposed       | 1 / 50 (2.00%)  | 5 / 138 (3.62%)  |
| occurrences (all)                 | 1               | 5                |
| Rhinitis                          |                 |                  |
| subjects affected / exposed       | 0 / 50 (0.00%)  | 5 / 138 (3.62%)  |
| occurrences (all)                 | 0               | 7                |
| Tonsillitis                       |                 |                  |
| subjects affected / exposed       | 1 / 50 (2.00%)  | 3 / 138 (2.17%)  |
| occurrences (all)                 | 2               | 5                |
| Oral herpes                       |                 |                  |
| subjects affected / exposed       | 0 / 50 (0.00%)  | 2 / 138 (1.45%)  |
| occurrences (all)                 | 0               | 2                |
| Respiratory tract infection viral |                 |                  |
| subjects affected / exposed       | 1 / 50 (2.00%)  | 2 / 138 (1.45%)  |
| occurrences (all)                 | 1               | 2                |

|                             |                |                 |
|-----------------------------|----------------|-----------------|
| Folliculitis                |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 4 / 138 (2.90%) |
| occurrences (all)           | 0              | 4               |
| Herpes simplex              |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 3 / 138 (2.17%) |
| occurrences (all)           | 1              | 3               |
| Tooth abscess               |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 2 / 138 (1.45%) |
| occurrences (all)           | 0              | 2               |
| Tooth infection             |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 3 / 138 (2.17%) |
| occurrences (all)           | 0              | 3               |
| Urinary tract infection     |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 3 / 138 (2.17%) |
| occurrences (all)           | 0              | 3               |
| Viral infection             |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 1              | 3               |
| Cellulitis                  |                |                 |
| subjects affected / exposed | 2 / 50 (4.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 2              | 1               |
| Fungal skin infection       |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 1              | 1               |
| Herpes zoster               |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 2 / 138 (1.45%) |
| occurrences (all)           | 0              | 2               |
| Acarodermatitis             |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 3 / 138 (2.17%) |
| occurrences (all)           | 0              | 5               |
| Chlamydial infection        |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 1              | 1               |
| Conjunctivitis              |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |

|                             |                |                 |
|-----------------------------|----------------|-----------------|
| Ear infection               |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 2 / 138 (1.45%) |
| occurrences (all)           | 1              | 2               |
| Furuncle                    |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Gonorrhoea                  |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 2 / 138 (1.45%) |
| occurrences (all)           | 1              | 2               |
| Onychomycosis               |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 2 / 138 (1.45%) |
| occurrences (all)           | 1              | 2               |
| Otitis media                |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Urethritis                  |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 2 / 138 (1.45%) |
| occurrences (all)           | 1              | 2               |
| Gastroenteritis viral       |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 1              | 1               |
| Herpes virus infection      |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 1              | 1               |
| Nasopharyngitis             |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 2               |
| Pharyngitis streptococcal   |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Tinea pedis                 |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Amoebic dysentery           |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |

|                             |                |                 |
|-----------------------------|----------------|-----------------|
| Angular cheilitis           |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 1              | 0               |
| Bacteriuria                 |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Body tinea                  |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Cystitis                    |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Dermatophytosis             |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Diverticulitis              |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 2 / 138 (1.45%) |
| occurrences (all)           | 0              | 3               |
| Fungal infection            |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Genital herpes              |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |
| Giardiasis                  |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Hepatitis C                 |                |                 |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 1              | 1               |
| Laryngitis                  |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)           | 0              | 1               |
| Molluscum contagiosum       |                |                 |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)           | 0              | 0               |

|                                |                |                 |
|--------------------------------|----------------|-----------------|
| Otitis externa                 |                |                 |
| subjects affected / exposed    | 0 / 50 (0.00%) | 2 / 138 (1.45%) |
| occurrences (all)              | 0              | 2               |
| Papilloma viral infection      |                |                 |
| subjects affected / exposed    | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)              | 0              | 0               |
| Shigella infection             |                |                 |
| subjects affected / exposed    | 0 / 50 (0.00%) | 2 / 138 (1.45%) |
| occurrences (all)              | 0              | 2               |
| Staphylococcal infection       |                |                 |
| subjects affected / exposed    | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)              | 3              | 0               |
| Subcutaneous abscess           |                |                 |
| subjects affected / exposed    | 0 / 50 (0.00%) | 2 / 138 (1.45%) |
| occurrences (all)              | 0              | 2               |
| Superinfection bacterial       |                |                 |
| subjects affected / exposed    | 1 / 50 (2.00%) | 1 / 138 (0.72%) |
| occurrences (all)              | 1              | 1               |
| Vulvovaginal mycotic infection |                |                 |
| subjects affected / exposed    | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)              | 2              | 0               |
| Acute hepatitis C              |                |                 |
| subjects affected / exposed    | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)              | 0              | 1               |
| Acute sinusitis                |                |                 |
| subjects affected / exposed    | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)              | 0              | 0               |
| Anal abscess                   |                |                 |
| subjects affected / exposed    | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)              | 0              | 0               |
| Anal infection                 |                |                 |
| subjects affected / exposed    | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)              | 1              | 0               |
| Anorectal infection            |                |                 |
| subjects affected / exposed    | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)              | 0              | 1               |

|                                   |                |                 |
|-----------------------------------|----------------|-----------------|
| Candida infection                 |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |
| Endometritis                      |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |
| Enterocolitis viral               |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |
| Epididymitis                      |                |                 |
| subjects affected / exposed       | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 1              | 0               |
| External ear cellulitis           |                |                 |
| subjects affected / exposed       | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 1              | 0               |
| Febrile infection                 |                |                 |
| subjects affected / exposed       | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 1              | 0               |
| Gastritis viral                   |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                 | 0              | 1               |
| Gastroenteritis shigella          |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |
| Genital herpes simplex            |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                 | 0              | 1               |
| Genital infection fungal          |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |
| Genitourinary chlamydia infection |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                 | 0              | 1               |
| Gingivitis                        |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |

|                                   |                |                 |
|-----------------------------------|----------------|-----------------|
| Helicobacter infection            |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |
| Impetigo                          |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                 | 0              | 1               |
| Infection                         |                |                 |
| subjects affected / exposed       | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 1              | 0               |
| Joint abscess                     |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |
| Lower respiratory tract infection |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                 | 0              | 1               |
| Lymphogranuloma venereum          |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                 | 0              | 1               |
| Neurosyphilis                     |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |
| Paronychia                        |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |
| Periodontitis                     |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 0              | 0               |
| Pilonidal cyst                    |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                 | 0              | 1               |
| Pneumonia                         |                |                 |
| subjects affected / exposed       | 1 / 50 (2.00%) | 0 / 138 (0.00%) |
| occurrences (all)                 | 1              | 0               |
| Primary syphilis                  |                |                 |
| subjects affected / exposed       | 0 / 50 (0.00%) | 1 / 138 (0.72%) |
| occurrences (all)                 | 0              | 1               |

|                                                                                   |                     |                      |
|-----------------------------------------------------------------------------------|---------------------|----------------------|
| Proctitis gonococcal<br>subjects affected / exposed<br>occurrences (all)          | 1 / 50 (2.00%)<br>1 | 0 / 138 (0.00%)<br>0 |
| Pulpitis dental<br>subjects affected / exposed<br>occurrences (all)               | 1 / 50 (2.00%)<br>1 | 0 / 138 (0.00%)<br>0 |
| Pyelonephritis acute<br>subjects affected / exposed<br>occurrences (all)          | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |
| Rash pustular<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |
| Rubella<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |
| Secondary syphilis<br>subjects affected / exposed<br>occurrences (all)            | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |
| Sialoadenitis<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |
| Skin candida<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |
| Staphylococcal skin infection<br>subjects affected / exposed<br>occurrences (all) | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |
| Tinea cruris<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |
| Tinea infection<br>subjects affected / exposed<br>occurrences (all)               | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |
| Toxocariasis<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |

|                                                                                       |                     |                      |  |
|---------------------------------------------------------------------------------------|---------------------|----------------------|--|
| Urethritis gonococcal<br>subjects affected / exposed<br>occurrences (all)             | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Urinary tract infection bacterial<br>subjects affected / exposed<br>occurrences (all) | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Vaginal infection<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Viral pharyngitis<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 50 (0.00%)<br>0 | 1 / 138 (0.72%)<br>1 |  |
| Vulvovaginal candidiasis<br>subjects affected / exposed<br>occurrences (all)          | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Metabolism and nutrition disorders                                                    |                     |                      |  |
| Vitamin D deficiency<br>subjects affected / exposed<br>occurrences (all)              | 0 / 50 (0.00%)<br>0 | 4 / 138 (2.90%)<br>4 |  |
| Hyperglycaemia<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 50 (0.00%)<br>0 | 3 / 138 (2.17%)<br>3 |  |
| Hyperlipidaemia<br>subjects affected / exposed<br>occurrences (all)                   | 1 / 50 (2.00%)<br>1 | 1 / 138 (0.72%)<br>1 |  |
| Decreased appetite<br>subjects affected / exposed<br>occurrences (all)                | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Gout<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 50 (0.00%)<br>0 | 2 / 138 (1.45%)<br>2 |  |
| Hypercholesterolaemia<br>subjects affected / exposed<br>occurrences (all)             | 0 / 50 (0.00%)<br>0 | 0 / 138 (0.00%)<br>0 |  |
| Hyperinsulinaemia                                                                     |                     |                      |  |

|                             |                |                 |  |
|-----------------------------|----------------|-----------------|--|
| subjects affected / exposed | 0 / 50 (0.00%) | 2 / 138 (1.45%) |  |
| occurrences (all)           | 0              | 2               |  |
| Diabetes mellitus           |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)           | 0              | 1               |  |
| Fat redistribution          |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)           | 0              | 0               |  |
| Fluid retention             |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)           | 0              | 0               |  |
| Hypertriglyceridaemia       |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 138 (0.72%) |  |
| occurrences (all)           | 0              | 1               |  |
| Hyponatraemia               |                |                 |  |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)           | 1              | 0               |  |
| Type 2 diabetes mellitus    |                |                 |  |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 138 (0.00%) |  |
| occurrences (all)           | 0              | 0               |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date           | Amendment                                                                                                                                                                                                                                                                                                                                                    |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 27 March 2009  | <ul style="list-style-type: none"><li>• Incorporation of text to comply with GlaxoSmithKline Policy 408</li><li>• Deletion of previous Section 6.4.6.2 and reformatting of entry criteria to comply with new standards.</li></ul>                                                                                                                            |
| 18 June 2009   | <ul style="list-style-type: none"><li>• Removal of exclusion of women of childbearing potential following availability of final embryo-fetal toxicology data</li><li>• Inclusion of additional toxicology data and exclusion criteria and toxicity management guidelines</li><li>• Correction of minor typographical errors and stylistic changes.</li></ul> |
| 14 August 2009 | <ul style="list-style-type: none"><li>• Change minimum entry cluster of differentiation 4 (CD4) plus cell criterion to greater than and equal to 200 cells/cubic millimeter (mm<sup>3</sup>)</li></ul>                                                                                                                                                       |
| 31 August 2009 | <ul style="list-style-type: none"><li>• Correction of omissions in Amendment No. 03</li><li>• Allow real-time urine pregnancy testing at Day 1.</li></ul>                                                                                                                                                                                                    |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported